| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Fate Therapeutics, Inc.$2.43
+0.02 (+0.83%)
C 55Pipeline Score Fair Value Biotech · Clinical
Market Cap
262.26 M
EPS
-1.09
P/E Ratio
-
Value Trade
17.32 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
1.30 M
R&D Expenses
24.70 M
Operating CF
-30.82 M
Total Assets
284.92 M
Total Liabilities
284.92 M
Equity
179.71 M
D/E Ratio
12,345
20.97 %
Week
61.87 %
1 Month
63.04 %
3 Month
125 %
6 Month
-97.13 %
5 Year
-65.7 %
All Time
Cash Data
Cash Position
174.82 M
Monthly Burn
10.27 M
Runway
14.5 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
564.08 K
52 Week Range
0.91 - 2.47
% held by Insiders
5.16 %
% held by Institutions
60.77 %
Enterprise Value
164.22 M
Total Shares
116.59 M
Short %
7.38 %
Float Shares
99.10 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Fate Therapeutics, Inc.
884Total events
4Upcoming
110Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T2Enrollment Complete
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationFT819Presentation
Subscribe to view catalyst details
TBD
▲Full ResultsFT819Clinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | FT836 | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-30 | FT836 | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-30 | FT836 | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
C55
Pipeline Score $648M
Pipeline ValueFair Value
Valuation Signal10
Drugs Scored2.5x
rNPV / MCap Top 85%
Micro Cap (rank 138 of 913)
Percentile RankFate Therapeutics, Inc. carries a moderate pipeline score (55/100), with $6.2B risk-adjusted pipeline value, led by FT825 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FT825 Small molecule | Advanced Solid Tumor | Phase 1 | NCT06241456 | 5% | $4.2B | RECRUITING | 351 | STALLED | C (41) | May 1, 2044 | HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
FT819 RMAT | Systemic Sclerosis | Phase 1 | 2026-07-06 | three of the four patients were treated under Regimen A; one patient was treated under Regimen B; All participants demonstrated a Revised Composite Response Index in Systemic Sclerosis (rCRISS)25 or higher; meaningful mean improvement in the Modified Rodnan Skin Score (mRSS) at 3 months post treatment; no Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Graft versus Host Disease (GvHD), hypogammaglobulinemia, or deaths reported Read More | Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting Read More | |
FT819 RMAT | Systemic Sclerosis | Phase 1 | 2026-07-06 | three of the four patients were treated under Regimen A; one patient was treated under Regimen B; All participants demonstrated a Revised Composite Response Index in Systemic Sclerosis (rCRISS)25 or higher; meaningful mean improvement in the Modified Rodnan Skin Score (mRSS) at 3 months post treatment; no Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Graft versus Host Disease (GvHD), hypogammaglobulinemia, or deaths reported Read More | Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting Read More | |
FT819 RMAT | Systemic Sclerosis | Phase 1 | 2026-07-06 | three of the four patients were treated under Regimen A; one patient was treated under Regimen B; All participants demonstrated a Revised Composite Response Index in Systemic Sclerosis (rCRISS)25 or higher; meaningful mean improvement in the Modified Rodnan Skin Score (mRSS) at 3 months post treatment; no Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Graft versus Host Disease (GvHD), hypogammaglobulinemia, or deaths reported Read More | Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FATE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FATE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FATE▲ +6.1%on this news
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
Fate Therapeutics has received FDA clearance for its Investigational New Drug application for FT839, a dual-CAR T cell product candidate targeting CD19 and CD38. This advancement allows the company to initiate a Phase 1/2 clinical trial to evaluate FT839's effectiveness in treating various autoimmune diseases. The therapy aims to eliminate pathogenic immune cells while avoiding the need for conditioning chemotherapy.
Read more →FATE▲ +6.1%on this newsshared move
Emerging Data with FT819: Favorable Tolerability and Clinical Activity in Systemic Sclerosis Using Off-the-Shelf, iPSC-Derived Anti-CD19 CAR T cells without Fludarabine
The article discusses the use of FT819, an iPSC-derived anti-CD19 CAR T cell therapy, in treating systemic sclerosis. It highlights favorable tolerability and clinical activity, although specific data and results are not provided in the text. The focus is on the innovative approach of using off-the-shelf CAR T cells without fludarabine.
Read more →FATEFate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics announced that preliminary clinical data for FT819, an off-the-shelf CAR T-cell product candidate, will be presented at the ISSCR 2026 Annual Meeting. The data highlights the treatment's safety and efficacy in patients with systemic sclerosis, demonstrating significant improvements without serious adverse effects. FT819 aims to address unmet needs in autoimmune diseases.
Read more →FATEWallace Rheumatic Center
The article discusses the privacy overview and cookie usage of the Wallace Rheumatic Center's website. It highlights the importance of cookies in enhancing user experience and tracking site usage through Google Analytics. The article emphasizes that strictly necessary cookies are always enabled to save user preferences.
Read more →FATEUniversity of Louisville
The article discusses the use of cookies on the University of Louisville's website, emphasizing their role in enhancing user experience. It mentions the collection of data through Google Analytics to understand site traffic and user preferences. The content is primarily focused on privacy and cookie management.
Read more →FATENicklaus Children’s Hospital
The article discusses the use of cookies on the Nicklaus Children's Hospital website. It highlights the importance of cookies for user experience and website functionality. Additionally, it mentions the use of Google Analytics for tracking visitor data. However, no specific news or updates about the hospital are provided.
Read more →FATEUniversity of Florida
The article discusses the use of cookies on the University of Florida's website, emphasizing their role in enhancing user experience and tracking site usage through Google Analytics. It outlines the necessity of strictly necessary cookies for saving user preferences and improving website functionality.
Read more →FATEFate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Fate Therapeutics, Inc. has announced its participation in several investor conferences during the third quarter of 2026. The conferences include the Leerink Partners Therapeutics Forum, Wells Fargo Healthcare Conference, Cantor Fitzgerald Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. The company aims to showcase its innovative pipeline of iPSC-derived cellular immunotherapies.
Read more →FATEFate Therapeutics Appoints Laura Hamill to Board of Directors
Fate Therapeutics has appointed Laura Hamill to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry. Her background in commercial operations and strategic management is expected to support the company's transition to a commercial-stage entity. Hamill's previous roles include significant positions at Gilead Sciences and Amgen, where she led substantial revenue growth.
Read more →FATEFate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Fate Therapeutics presented promising data for its CAR T-cell therapies, FT819 and FT839, at the European Congress of Rheumatology. FT819, currently in Phase 1 trials, has shown rapid and sustained clinical improvements in patients with systemic lupus erythematosus (SLE) while maintaining a favorable safety profile. Treatment led to significant B-cell depletion and possible reconstitution towards a healthier immune response. The preclinical data for FT839 indicates its potential efficacy in treating rheumatoid arthritis without the need for conditioning chemotherapy, positioning both therapies as transformative options for autoimmune diseases.
Read more →FATETRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies Accessible to AllTM CORPORATE PRESENTATION June 2026 | NASDAQ: FATE | Non-Confidential 2026 Fate Therapeutics. All ri
Fate Therapeutics is advancing its pipeline of CAR T-cell therapies aimed at treating autoimmune diseases and cancer. The company has initiated a registrational trial for its product FT819, which targets systemic lupus erythematosus. With a focus on off-the-shelf therapies, Fate aims to improve patient access and simplify treatment processes. However, potential risks include uncertainties in clinical outcomes and regulatory approvals, which could impact the timelines for commercial launches.
Read more →FATE▼ -5.3%on this news· ran to -19% by day 3shared move
FT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseases
The article discusses FT839, a novel dual-CAR T cell therapy designed to target pathogenic B and T cells in autoimmune diseases. It highlights the potential of this off-the-shelf treatment approach. However, specific details about clinical trials or results are not provided.
Read more →FATE▼ -5.3%on this news· ran to -19% by day 3shared move
Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Discharge
The article discusses a Phase 1 study evaluating the safety and efficacy of an off-the-shelf anti-CD19 CAR T-cell therapy with reduced conditioning in patients with systemic lupus erythematosus (SLE). The study supports the potential for same-day discharge following treatment. However, specific results and implications are not detailed in the provided text.
Read more →FATE▼ -13.6%on this news· ran to -26% by day 3shared move
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Fate Therapeutics announced the granting of restricted stock units (RSUs) to two new non-executive employees as part of their inducement plan. This grant, totaling 67,300 shares, was approved by the Compensation Committee and aligns with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, promoting employee retention.
Read more →FATEPreliminary Phase 1 Results of a MICA/B-targeted CAR T cell Designed to Overcome Solid Tumor Escape Mechanisms and Avoid the Requirement for Conditioning Chemotherapy
The article discusses preliminary Phase 1 results of a CAR T cell therapy targeting MICA/B, designed to address solid tumor escape mechanisms without the need for conditioning chemotherapy. However, the article lacks specific details on the results or implications of the study.
Read more →FATEFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
Fate Therapeutics presented promising clinical data for FT836 at the ASCO Annual Meeting, highlighting its ability to reduce tumor size in metastatic colorectal cancer without conditioning chemotherapy. The early Phase 1 results indicate favorable safety and efficacy, with no adverse effects reported. Notably, FT836 demonstrates the capacity for trafficking to tumor sites and persistence in tumor tissues. The company expresses optimism regarding its potential to transform treatment approaches for solid tumors, particularly in patients with limited options.
Read more →FATE▲ +14.1%on this news· ran to +29% by day 3
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics announced that it will present data on its off-the-shelf CAR T-cell therapies at the upcoming ASCO and EULAR annual meetings. The presentations will include preliminary results from the FT836 and FT819 programs, focusing on overcoming solid tumor escape mechanisms and improving patient discharge protocols. These advancements highlight the company's commitment to enhancing treatment options for cancer and autoimmune diseases.
Read more →FATE▼ -7.6%on this news
Off-the-Shelf Anti-CD19 CAR T-cell Therapy With Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
The article discusses the efficacy and tolerability of an off-the-shelf anti-CD19 CAR T-cell therapy in patients with systemic lupus erythematosus. The therapy shows promising results with reduced or no conditioning chemotherapy, which may facilitate better patient outcomes. The findings support plans for enrolling adolescents in future clinical trials.
Read more →FATE▼ -7.6%on this newsshared move
Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study
The article discusses a Phase 1 study on an off-the-shelf anti-CD19 CAR T-cell therapy with reduced conditioning in systemic lupus erythematosus (SLE). However, the content does not provide specific details about the study's findings or implications. The focus is primarily on cookie usage and website functionality.
Read more →FATE▼ -7.6%on this newsshared move
FT819 Drives B cell Compartment Remodeling of Patients with Systemic Lupus Erythematosus Without Conditioning Chemotherapy
The article discusses FT819's impact on B cell compartment remodeling in patients with systemic lupus erythematosus. Notably, this treatment was administered without the use of conditioning chemotherapy. The findings suggest potential advancements in therapeutic approaches for this condition, although specific results or implications are not detailed.
Read more →FATE▼ -7.6%on this newsshared move
CAR T cells Targeting pan-Tumor Antigens MICA/B can be Uniquely Combined with SOC Treatments without Conditioning Chemotherapy for Broad and Effective Therapeutic Application in Cancer
The article discusses the potential of CAR T cells targeting pan-Tumor antigens MICA/B in combination with standard of care treatments. It highlights the unique approach of utilizing these therapies without conditioning chemotherapy, suggesting a broad application in cancer treatment. However, specific details on efficacy or clinical outcomes are not provided.
Read more →FATE▼ -5.1%on this news· ran to -23% by day 3shared move
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Fate Therapeutics reported its Q1 2026 financial results, highlighting the upcoming initiation of the RECLAIM-LN Phase 2 trial for FT819 in lupus nephritis. The company has been selected for the FDA's CDRP program, enhancing its regulatory engagement. Financially, Fate has extended its runway into 2028, despite reporting a modest revenue of $1.3 million against operating expenses of $34.3 million.
Read more →FATE▼ -8.8%on this news· ran to -21% by day 3shared move
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Fate Therapeutics presented promising data on FT819, an off-the-shelf CAR T-cell therapy, at the 2026 ASGCT Annual Meeting. The treatment achieved significant clinical responses in patients with systemic lupus erythematosus (SLE) without the need for conditioning chemotherapy. Notably, patients demonstrated durable B cell remodeling, indicating potential long-term benefits. The company aims to enhance patient accessibility through its innovative therapies.
Read more →FATE▲ +31.1%on this news
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Fate Therapeutics has announced the selection of its therapy FT819 for participation in the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program. This program is designed to facilitate expedited manufacturing readiness for therapies with urgent clinical needs. FT819 is currently being investigated for the treatment of moderate-to-severe systemic lupus erythematosus and aims to address significant unmet medical needs in this patient population. The company's CEO emphasized that this selection brings them closer to delivering their innovative treatment to broader patient populations.
Read more →FATE▲ +17.6%on this news· ran to +59% by day 3shared move
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Fate Therapeutics announced the grant of 30,200 restricted stock units to a newly-hired employee under Nasdaq Listing Rule 5635(c)(4). This award, approved by the Compensation Committee, will vest over four years. The company is focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.
Read more →FATE▲ +17.6%on this news· ran to +59% by day 3shared move
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics announced three presentations at the upcoming ASGCT Annual Meeting, focusing on its off-the-shelf CAR T-cell therapies, including FT819, FT839, and FT836. The presentations will cover clinical data for FT819 in systemic lupus erythematosus, an oral presentation on FT839 targeting autoimmune diseases, and preclinical data for FT836 against various tumors. These advancements aim to enhance treatment options for cancer and autoimmune diseases.
Read more →FATE▲ +22.4%on this news· ran to +83% by day 3shared move
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. has announced the granting of restricted stock units (RSUs) totaling 30,200 shares to a newly-hired non-executive employee. This grant was approved by the Compensation Committee and aligns with Nasdaq Listing Rule 5635(c)(4). The RSUs are set to vest over four years, contingent on the employee's continued employment. This action reflects the company's commitment to attracting talent as it seeks to advance its iPSC-derived cellular immunotherapy pipeline.
Read more →FATEFate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
Fate Therapeutics announced that clinical data for its off-the-shelf CAR T-cell product candidate, FT819, will be presented at the CCR-East meeting. The data, derived from a Phase 1 trial, indicates significant improvements in disease activity among systemic lupus erythematosus patients. The presentation will highlight safety and efficacy results from 13 patients treated with FT819.
Read more →FATE▲ +6.2%on this news
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting
Fate Therapeutics announced the presentation of preclinical data for FT839, a next-generation CAR T-cell product candidate, at the AACR Annual Meeting. FT839 is designed for treating hematological malignancies and autoimmune diseases without conditioning chemotherapy. The product utilizes innovative technology to enhance immune response and persistence, showcasing its potential in the field.
Read more →FATE▲ +7.6%on this news
University College of London Hospitals NHS Trust (UCLH)
The article discusses the cookie policy of the University College of London Hospitals NHS Trust website. It emphasizes the use of cookies to enhance user experience and mentions the collection of data through Google Analytics. The content is primarily focused on privacy and user preferences regarding cookies.
Read more →FATE▲ +7.6%on this newsshared move
Cambridge University Hospitals NHS Foundation Trust
The article discusses the cookie policy of Cambridge University Hospitals NHS Foundation Trust's website. It outlines the use of cookies for user experience enhancement and data collection through Google Analytics. The content primarily focuses on privacy and user preferences regarding cookie settings.
Read more →FATE▲ +7.6%on this newsshared move
Manchester University NHS Foundation Trust
The article discusses the privacy policy and cookie usage of the Manchester University NHS Foundation Trust website. It highlights the importance of cookies in enhancing user experience and tracking website analytics. The content primarily focuses on technical aspects rather than specific news events or developments.
Read more →FATE▲ +7.6%on this newsshared move
Uppsala University
The article discusses the use of cookies on the Uppsala University website. It explains how cookies enhance user experience by recognizing returning visitors and collecting data on site usage. Additionally, the article mentions the importance of strictly necessary cookies for saving user preferences.
Read more →FATE▲ +7.6%on this newsshared move
Hôpital La Pitié Salpêtrière
The article discusses the use of cookies on a website, emphasizing their role in enhancing user experience. It mentions the collection of data through Google Analytics to understand visitor behavior. However, it does not provide specific news or developments related to the ticker FATE.
Read more →FATE▲ +7.6%on this newsshared move
Regional One Health
The article provides an overview of cookie usage on the Regional One Health website, emphasizing the importance of cookies for user experience and site functionality. It mentions the use of Google Analytics for tracking visitor data and improving website performance. Additionally, it highlights the privacy policy for data collection.
Read more →FATE▲ +7.6%on this newsshared move
Jefferson Einstein Hospital Philadelphia
The article provides an overview of the cookie policy and privacy practices of Jefferson Einstein Hospital in Philadelphia. It details the use of cookies for enhancing user experience and analytics. There are no specific news events or updates mentioned in the text.
Read more →FATE▲ +7.6%on this newsshared move
University of Oklahoma
The article primarily discusses the use of cookies on the University of Oklahoma's website. It outlines how cookies enhance user experience by recognizing returning visitors and tracking site usage through Google Analytics. The article emphasizes the importance of cookie settings for privacy and user preferences.
Read more →FATE▲ +7.6%on this newsshared move
MetroHealth
The article discusses the use of cookies on the MetroHealth website, emphasizing the importance of user experience and data collection. It mentions that cookies help recognize returning users and improve website functionality. Additionally, it highlights the use of Google Analytics for tracking site visitors and popular pages.
Read more →FATE▲ +7.6%on this newsshared move
Duke University Health System
The article provides an overview of the cookie policy and data collection practices of Duke University Health System's website. It emphasizes the use of cookies for enhancing user experience and mentions the role of Google Analytics in tracking site usage. No specific news or developments are reported.
Read more →FATE▲ +7.6%on this newsshared move
Montefiore Medical Center
The article discusses the cookie policy and privacy overview of the Montefiore Medical Center website. It highlights the use of cookies for enhancing user experience and collecting analytics data. The information emphasizes the importance of cookie settings and user preferences.
Read more →FATE▲ +7.6%on this newsshared move
University of Nebraska Medical Center
The article discusses the cookie policy and privacy overview of the University of Nebraska Medical Center's website. It outlines the use of cookies for user experience enhancement and data collection through Google Analytics. The article emphasizes the importance of strictly necessary cookies for saving user preferences.
Read more →FATE▲ +7.6%on this newsshared move
University of Minnesota Medical School
The article primarily discusses the use of cookies on the University of Minnesota Medical School's website. It highlights the importance of cookies for user experience and website functionality, including user recognition and data collection through Google Analytics. There are no specific news events or updates mentioned.
Read more →FATE▲ +7.6%on this newsshared move
University of California San Francisco
The article discusses the use of cookies on the University of California San Francisco website. It highlights the importance of cookies in providing a better user experience by recognizing returning visitors and analyzing site usage. The article also mentions the use of Google Analytics for tracking visitor data.
Read more →FATE▲ +7.6%on this newsshared move
Children’s Hospital Los Angeles Division Of Rheumatology
The article discusses the privacy policy and cookie usage of the Children's Hospital Los Angeles Division of Rheumatology website. It emphasizes the importance of cookies for user experience and site functionality. Additionally, it mentions the use of Google Analytics for tracking visitor data to improve the website.
Read more →FATE▲ +7.6%on this newsshared move
University of California Irvine
The article discusses the use of cookies on the University of California Irvine's website, emphasizing the importance of user experience and data collection through Google Analytics. It outlines how cookies function to enhance website performance and user recognition. Additionally, it mentions the availability of a Privacy Policy for more detailed information.
Read more →FATE▲ +7.6%on this newsshared move
Providence Medical Foundation
The article discusses the use of cookies on the Providence Medical Foundation website. It emphasizes the importance of cookie settings for user experience and mentions the use of Google Analytics for tracking visitor data. The content is primarily focused on privacy and user preferences.
Read more →FATE▲ +7.6%on this newsshared move
The University of Texas MD Anderson Cancer Center
The article provides an overview of the cookie policy and privacy practices of the University of Texas MD Anderson Cancer Center's website. It highlights the use of cookies for user experience and analytics. There are no specific news events or updates mentioned.
Read more →FATE▲ +7.6%on this newsshared move
Sarah Cannon Research Institute (SCRI) – Oncology Partners
The article discusses the privacy policies and cookie usage on the Sarah Cannon Research Institute's website. It emphasizes the importance of cookies for user experience and website functionality. Additionally, it mentions the use of Google Analytics for tracking visitor data to improve the website.
Read more →FATE▲ +7.6%on this newsshared move
Thomas Jefferson University, Sidney Kimmel Cancer Center
The article primarily discusses the use of cookies on the Thomas Jefferson University and Sidney Kimmel Cancer Center website. It outlines the types of cookies used, including strictly necessary cookies and third-party cookies, and emphasizes the importance of cookies for user experience and website analytics.
Read more →FATE▲ +7.6%on this newsshared move
OU Health Stephenson Cancer Center
The article discusses the use of cookies on the OU Health Stephenson Cancer Center website, emphasizing the importance of user experience and data collection through analytics. It outlines the types of cookies used and their functions, particularly in recognizing returning visitors and improving website performance. The article also mentions the availability of a Privacy Policy for further information.
Read more →FATE▲ +7.6%on this newsshared move
Ohio State University – Comprehensive Cancer Center
The article primarily discusses the privacy policy and cookie usage for the Ohio State University Comprehensive Cancer Center website. It outlines how cookies enhance user experience by recognizing returning visitors and gathering analytics data. There are no specific news events or updates regarding cancer research or clinical trials mentioned.
Read more →FATE▲ +7.6%on this newsshared move
Oncology Hematology Care Clinial Trials
The article discusses the use of cookies on a website to enhance user experience. It outlines the types of cookies used, including strictly necessary cookies and third-party cookies. Additionally, it mentions the use of Google Analytics for tracking visitor data and improving website functionality.
Read more →FATE▲ +7.6%on this newsshared move
Memorial Sloan Kettering Cancer Center
The article discusses the privacy policies and cookie usage of the Memorial Sloan Kettering Cancer Center website. It highlights the importance of cookies for user experience and website functionality. Additionally, it mentions the use of Google Analytics for tracking visitor data to enhance the site. No specific news or events are detailed.
Read more →FATE▲ +7.6%on this newsshared move
Washington University School of Medicine
The article provides an overview of the cookie policy and privacy practices of the Washington University School of Medicine's website. It highlights the use of cookies to enhance user experience and track website analytics. The document emphasizes the importance of user privacy and provides a link to the privacy policy for more details.
Read more →FATE▲ +7.6%on this newsshared move
Karmanos Cancer Institute
The article discusses the privacy policy and cookie usage of the Karmanos Cancer Institute's website. It emphasizes the importance of cookies for user experience and website functionality. Additionally, it mentions the use of Google Analytics for tracking visitor data and improving the site.
Read more →FATE▲ +7.6%on this newsshared move
University of Chicago Medical Center
The article provides an overview of the cookie policy and privacy practices of the University of Chicago Medical Center's website. It outlines the use of cookies to enhance user experience and mentions the role of Google Analytics in tracking site usage. There are no specific news events or updates discussed.
Read more →FATE▲ +7.6%on this newsshared move
Yale New Haven Hospital – Yale Cancer Center
The article discusses the use of cookies on the Yale New Haven Hospital and Yale Cancer Center website. It highlights the importance of cookies for user experience and website functionality, including recognizing returning users and collecting analytics data. The article also references the site's Privacy Policy for more information on data collection.
Read more →FATE▲ +7.6%on this newsshared move
University of California San Diego Moores Cancer Center
The article discusses the privacy practices of the University of California San Diego Moores Cancer Center's website. It highlights the use of cookies for enhancing user experience and mentions the collection of data through Google Analytics. However, it does not provide specific news or developments related to the cancer center.
Read more →FATE▲ +7.6%on this newsshared move
Banner MD Anderson Cancer Center
The article provides an overview of the privacy policy and cookie usage on the Banner MD Anderson Cancer Center website. It emphasizes the importance of cookies for user experience and mentions the use of Google Analytics for site improvement. There are no specific news events or updates discussed.
Read more →FATE▲ +7.6%on this newsshared move
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
Fate Therapeutics, Inc. has announced its participation in five investor conferences during the second quarter of 2026. These events include the Needham Virtual Healthcare Conference and the Goldman Sachs Global Healthcare Conference, among others. The company aims to present its pioneering work in iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. Webcasts of the presentations will be available on their website.
Read more →FATEFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Fate Therapeutics has announced the granting of restricted stock units (RSUs) to a newly-hired non-executive employee as part of its inducement plan. The award includes 7,260 shares, which will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's ongoing commitment to attract talent in the biopharmaceutical sector.
Read more →FATEM. D. Anderson Cancer Center
The article discusses the use of cookies on the M. D. Anderson Cancer Center website, emphasizing the importance of user experience and data collection through Google Analytics. It outlines how cookies function to enhance site navigation and user preferences. Additionally, it references the Privacy Policy for more information on data collection.
Read more →FATEUniversity of Minnesota Masonic Cancer Center
The article provides an overview of the privacy policy and cookie usage on the University of Minnesota Masonic Cancer Center's website. It discusses the importance of cookies for user experience and website functionality, as well as the use of Google Analytics for tracking visitor data. No specific news or developments are mentioned.
Read more →FATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - March 4, 2026
Fate Therapeutics announced the grant of restricted stock units (RSUs) to three new non-executive employees as part of their inducement to join the company. The RSUs, totaling 50,700 shares, will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's ongoing commitment to its workforce and innovative pipeline.
Read more →FATE▲ +5.8%on this newsshared move
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Fate Therapeutics, Inc. will participate in the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026. Management will host a fireside chat and investor meetings, highlighting their innovative iPSC-derived cellular immunotherapies. A live webcast will be available, with an archived replay for 90 days post-event.
Read more →FATE▲ +5.4%on this news
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Fate Therapeutics reported positive advancements in its CAR T-cell therapies, particularly FT819, which has shown promising results in outpatient settings for autoimmune diseases. The company has expanded its Phase 1 enrollment and achieved significant milestones, including patient improvements and reduced operating expenses. With a strong financial position, Fate aims to continue its progress towards commercialization.
Read more →FATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2026
Fate Therapeutics announced the granting of stock options and restricted stock units to a newly-hired employee as part of its inducement plan. The grants include 120,000 stock options at an exercise price of $1.19 and 90,000 restricted stock units, both vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and showcases the company's commitment to attracting talent.
Read more →FATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2026
Fate Therapeutics announced the granting of stock options and restricted stock units to newly-hired employees as part of its inducement equity plan. This move aims to attract talent to support the company's development of iPSC-derived cellular immunotherapies. The stock options and RSUs will vest over a four-year period, contingent on continued employment.
Read more →FATEDevelopment of Next Generation Multi-Antigen Targeting Off-the Shelf CAR T-Cells for Conditioning-Free Treatment of B-Cell Lymphoma
The article discusses the development of next-generation CAR T-cells aimed at treating B-cell lymphoma without the need for conditioning. It highlights the innovative approach of multi-antigen targeting to enhance treatment efficacy. However, specific details regarding the research progress or results are not provided.
Read more →FATEThe Development of and Off-the-Shelf CAR T-Cell Therapy Targeting CD19 and CD38 for Broad Application in Autoimmune Disease
The article discusses the development of an off-the-shelf CAR T-cell therapy targeting CD19 and CD38 for potential applications in autoimmune diseases. However, the content primarily focuses on website privacy and cookie usage, lacking detailed information on the therapy itself.
Read more →FATETargeting of Tumor Antigen CD38 and Stress Antigens MICA/B by CAR T-Cells Provides a Unique Approach for the Comprehensive Treatment of Multiple Myeloma
The article discusses the targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T-cells as a novel strategy for treating multiple myeloma. It highlights the potential benefits of this approach in providing comprehensive treatment options. However, specific details on the research findings or clinical implications are not provided.
Read more →FATEFate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
Fate Therapeutics presented updated Phase 1 clinical data on its FT819 CAR T-cell product for systemic lupus erythematosus at the 2025 ASH Annual Meeting. The results indicate meaningful disease response and a favorable safety profile among treated patients. Additionally, preclinical data for next-generation programs FT836 and FT839 highlight advancements in targeting mechanisms for autoimmune diseases and hematologic malignancies. The ongoing pipeline development aims to improve accessibility and therapeutic outcomes for a broad patient population.
Read more →FATEFate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate Therapeutics will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2, 2025. The company's management will participate in a fireside chat and a cell therapy panel discussion, highlighting its focus on advanced cellular immunotherapies. Fate Therapeutics is known for its innovative use of induced pluripotent stem cells in creating off-the-shelf cellular therapies for cancer and autoimmune diseases. The presentations will be available for live streaming and later access on the company’s website.
Read more →FATEFate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Fate Therapeutics reported its third quarter 2025 financial results, highlighting significant advancements in its CAR T-cell programs. The company received authorization from UK and EU authorities to activate clinical trial sites for FT819, which targets CD19 and aims to improve patient accessibility. Additionally, FT836 has been introduced for solid tumors, showcasing the company's innovative approach to treatment. Fate Therapeutics maintains a strong financial position with $226 million in cash, supporting its operations through 2027.
Read more →FATE▼ -8.4%on this news
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics announced the granting of restricted stock units (RSUs) to three new non-executive employees as part of their inducement awards under Nasdaq Listing Rule 5635(c)(4). The RSUs, totaling 34,700 shares, will vest over four years, contingent on the employees' continued employment. This move reflects the company's ongoing commitment to its workforce and its innovative pipeline in cellular immunotherapies.
Read more →FATELongitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-derived CAR T-cell Therapy
The article discusses the longitudinal analysis of B cell remodeling in patients with systemic lupus erythematosus (SLE) following treatment with iPSC-derived CAR T-cell therapy. It highlights the importance of understanding the immune response in SLE and the potential implications for future therapies. However, specific results or findings from the analysis are not provided.
Read more →FATE▼ -6.1%on this news· ran to -22% by day 3shared move
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Fate Therapeutics presented new clinical data for FT819, an off-the-shelf CAR T-cell therapy, at ACR Convergence 2025. In a Phase 1 trial involving 10 patients with treatment-refractory systemic lupus erythematosus (SLE), the therapy demonstrated a favorable safety profile and significant clinical activity. Notably, patients showed reductions in disease activity scores, and some achieved complete renal response. The company plans to expand the trial and engage with the FDA for a pivotal study.
Read more →FATE▼ -6.1%on this news· ran to -22% by day 3shared move
iPSC-Derived, Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
The article discusses the use of iPSC-derived, off-the-shelf anti-CD19 CAR T cells in treating lupus. It highlights improved clinical outcomes with reduced or no conditioning chemotherapy. However, specific details about the study results or implications are not provided in the text.
Read more →FATELymphoma
Lymphoma is a type of cancer that originates from uncontrolled growth of lymphocytes, a kind of white blood cell. These cells are crucial for the immune system, and their excessive accumulation can occur in lymph nodes, spleen, or bone marrow. Common symptoms include fatigue, weight loss, and fevers.
Read more →FATEMultiple Myeloma (MM)
Multiple Myeloma (MM) is a condition characterized by uncontrolled growth of plasma cells in the bone marrow. This abnormal proliferation leads to the crowding out of healthy blood cells and the production of harmful proteins affecting bones, kidneys, and the immune system. Common symptoms include bone pain, fatigue, and frequent infections.
Read more →FATESolid Tumors
The article discusses solid tumors, which can develop in various parts of the body such as organs, muscles, and bones. It highlights that malignant tumors can metastasize to other regions. Common types of solid tumors include breast, ovarian, lung, and colorectal cancers, with symptoms varying based on tumor location.
Read more →FATEIdiopathic Inflammatory Myositis (IIM)
The article discusses Idiopathic Inflammatory Myositis (IIM), a group of chronic autoimmune diseases characterized by muscle inflammation and weakness. It outlines the main types of IIM, including Dermatomyositis, IMNM, ASyS, and IBM, each with distinct symptoms and effects on the body. The immune system's role in attacking muscles and organs is emphasized.
Read more →FATEAnca-Associated Vasculitis (AAV)
ANCA-Associated Vasculitis (AAV) encompasses autoimmune diseases that cause inflammation in small to medium blood vessels, potentially leading to organ damage. The article outlines three primary types of AAV: Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA), and Eosinophilic granulomatosis with polyangiitis (EGPA), each with distinct characteristics and organ involvement.
Read more →FATESystemic Sclerosis (SSC)
Systemic Sclerosis (SSc), also known as scleroderma, is a chronic autoimmune condition characterized by the immune system's attack on healthy tissues. This results in inflammation and excessive collagen production, leading to the hardening of the skin, blood vessels, and internal organs. The severity and type of symptoms can vary based on the organs involved.
Read more →FATESystemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the immune system attacking healthy tissues, leading to inflammation and damage in various organs. Symptoms can vary significantly, including fatigue, joint pain, and skin rashes. The condition is marked by unpredictable flare-ups and periods of remission.
Read more →FATE▲ +7.9%on this news
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
Fate Therapeutics has appointed Kamal Adawi as Chief Financial Officer, effective October 20, 2025. Adawi brings over 20 years of financial leadership experience in the life sciences sector, particularly in autoimmune diseases. His role is expected to enhance the company's strategy as it progresses with its clinical programs, including the development of FT819 for systemic lupus erythematosus.
Read more →FATE▼ -5.2%on this news
Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences. The company focuses on developing off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). Presentations will be available via live webcast on their website, showcasing their innovative pipeline.
Read more →FATEFate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus ne
Fate Therapeutics announced positive second quarter 2025 results, highlighting that the first patient treated with their FT819 CAR T-cell product showed significant improvement in lupus nephritis. The company has received RMAT designation and is working on FDA feedback to advance their registrational studies for moderate-to-severe systemic lupus erythematosus. They reported a solid financial position with $249 million in reserves, extending their operational runway through the end of 2027. The progress in their clinical programs reinforces their commitment to making cell therapies accessible, while also indicating challenges in clinical trial enrollment for further studies.
Read more →FATENext-Generation Off-the-Shelf CAR T-Cells: A Novel Platform to Enable Comprehensive Elimination of Aberrant Effector Cells for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
The article discusses a novel platform for off-the-shelf CAR T-cells aimed at treating autoimmune diseases without the need for conditioning chemotherapy. It highlights the potential for comprehensive elimination of aberrant effector cells. However, specific details about the platform's efficacy or clinical applications are not provided.
Read more →FATENext Generation CAR-NK cell Therapy Leverages Alloimmune Defense Technology to Persist Without Conditioning Chemotherapy for the Treatment of Autoimmune Disease
The article discusses a next-generation CAR-NK cell therapy that utilizes alloimmune defense technology. This innovative approach aims to treat autoimmune diseases without the need for conditioning chemotherapy. The therapy's potential benefits and mechanisms are highlighted, but specific details on clinical outcomes or trials are not provided.
Read more →FATE▼ -7.2%on this news· ran to -26% by day 3
Treatment of Refractory SLE with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy
The article discusses the treatment of refractory systemic lupus erythematosus (SLE) using off-the-shelf iPSC-derived anti-CD19 CAR T-cell therapy. It highlights the potential benefits of this innovative approach but does not provide specific results or outcomes. The focus is on the therapy's application and relevance in treating this challenging condition.
Read more →FATE▼ -7.2%on this news· ran to -26% by day 3shared move
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
Fate Therapeutics presented updated clinical data for their CAR T-cell product FT819 at the EULAR 2025 Congress, highlighting significant efficacy in treating severe lupus nephritis. All three patients treated showed a positive renal response, with the first patient maintaining drug-free remission for over a year. Additionally, FT819's lower conditioning requirements and favorable safety profile may enhance its clinical applicability. The company plans to expand its investigations into multiple autoimmune diseases and will engage with the FDA regarding regulatory strategies for FT819.
Read more →FATE▼ -8.3%on this news
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors San Diego, CA
Fate Therapeutics has appointed Matthew Abernethy, an experienced finance executive with expertise in the biotech sector, to its Board of Directors as of May 29, 2025. His extensive background in corporate finance and investor relations will support the company's efforts in advancing its pipeline of off-the-shelf cellular immunotherapies for autoimmunity and oncology. Concurrently, Timothy P. Coughlin stepped down from the board. Abernethy expressed his commitment to enhancing patient outcomes through innovative cell therapies.
Read more →FATEFate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Fate Therapeutics is set to present clinical and preclinical data regarding its off-the-shelf CAR T-cell product candidate, FT819, for treating systemic lupus erythematosus at the EULAR 2025 Congress in Barcelona. The Phase 1 clinical trial will assess the safety and efficacy of FT819 in patients undergoing varied treatment regimens. The company's innovative iPSC product platform aims to streamline therapy access and effectiveness, addressing challenges posed by conditioning chemotherapy.
Read more →FATE▲ +14%on this news
FT836, a Novel MICA/B-targeting CAR T-cell Therapy Engineered to Eliminate the Need for Conditioning Chemotherapy with Broad Activity Across Solid Tumor Indications
The article discusses FT836, a novel CAR T-cell therapy designed to target MICA/B and eliminate the need for conditioning chemotherapy. It aims to demonstrate broad activity across various solid tumor indications. However, specific details about its efficacy or clinical trial results are not provided in the text.
Read more →FATE▲ +14%on this newsshared move
Targeting uPAR with Multiplexed-Engineered iPSC-Derived CAR T Cells to Reverse Age- and Insult-Related Fibrotic Disease
The article discusses the use of multiplexed-engineered iPSC-derived CAR T cells targeting uPAR to address fibrotic diseases related to aging and other insults. However, the content primarily focuses on website privacy policies and cookie usage, lacking specific details about the research or its implications.
Read more →FATE▲ +14%on this newsshared move
Next-Generation Off-the-Shelf CAR T-Cell Therapies for Conditioning-Free Treatment of a Broad Spectrum of In collaboration with Autoimmune Diseases and Hematologic Malignancies
The article discusses next-generation off-the-shelf CAR T-cell therapies aimed at treating autoimmune diseases and hematologic malignancies. However, it primarily focuses on privacy and cookie usage on the website, lacking substantial information on the therapies themselves.
Read more →FATE▲ +14%on this newsshared move
Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
The article discusses the use of an alloimmune defense receptor combined with the genetic ablation of the adhesion ligand CD58. This approach aims to enhance the functional persistence of allogeneic cell therapies without the need for conditioning chemotherapy. The focus is on improving therapeutic outcomes in cell therapy applications.
Read more →FATE▲ +14%on this newsshared move
Phase 1 Translational Assessment of an Off-The-Shelf CAR NK Cell Armed with Alloimmune Defense Technology for Conditioning-free Therapy
The article discusses a Phase 1 translational assessment of an off-the-shelf CAR NK cell therapy that utilizes alloimmune defense technology. This therapy aims to provide conditioning-free treatment options. However, the article lacks specific details about the study's outcomes or implications.
Read more →FATE▼ -6.5%on this news
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Fe
Fate Therapeutics has announced its financial results for Q1 2025, highlighting important advancements in its FT819 CAR T-cell program for moderate-to-severe systemic lupus erythematosus (SLE). The company received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, allowing expedited review of its therapy. Additionally, Fate is expanding its Phase 1 study to encompass multiple B cell-mediated autoimmune diseases while boasting a cash reserve projected to sustain operations until mid-2027. New clinical data from the ongoing FT819 study will be presented at the EULAR 2025 Congress in June.
Read more →FATE▼ -6.4%on this newsshared move
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Fate Therapeutics, Inc. has announced that five presentations related to its off-the-shelf CAR T-cell product platform will take place at the ASGCT Annual Meeting in May 2025. This includes an oral presentation on FT522, a CAR NK cell candidate designed to function without the need for conditioning chemotherapy. The company will also share preclinical data from various therapeutic applications involving their iPSC-derived CAR T-cell products. This event signifies a crucial step in advancing their clinical research and product development efforts.
Read more →FATE▼ -12.8%on this news
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Fate Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to FT819, a CAR T-cell therapy developed for treating moderate to severe systemic lupus erythematosus (SLE). This designation recognizes the therapy's potential to address significant unmet medical needs and facilitates enhanced dialogue with the FDA throughout its development process. Initial data from a Phase 1 study has shown promise regarding safety and efficacy, and further results are expected to be presented at upcoming medical conferences. The design of FT819 aims to provide a more accessible and cost-effective treatment option for lupus patients.
Read more →FATE▼ -8.2%on this news
Lilly Wong, Ph.D.
Lilly Wong, Ph.D., has been appointed Vice President of Clinical Translation at Fate Therapeutics. She will oversee the development of translational strategies for clinical programs in hematology-oncology, solid tumors, and autoimmune diseases. Dr. Wong brings over 20 years of experience, previously serving at Bristol Myers Squibb and Celgene Corporation.
Read more →FATE▲ +14.9%on this newsshared move
Vaneet Sandhu, M.D.
Vaneet K Sandhu, M.D., is the Vice President of Clinical Development at Fate Therapeutics, focusing on autoimmunity. She has a strong background as a rheumatologist and has contributed to various clinical trials and research initiatives. Sandhu holds an MBBS from India and an MS in Academic Medicine from the University of Missouri.
Read more →FATEFate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning
Fate Therapeutics, Inc. reported its fourth quarter and full year 2024 financial results, highlighting significant advancements in its clinical programs. A Phase 1 dose expansion for FT819, targeting moderate-to-severe systemic lupus erythematosus (SLE), has been initiated, and the company aims to treat additional autoimmune diseases based on FDA collaboration. Financially, Fate has a robust position with $307 million available, ensuring operations continue through 2026. Moreover, promising initial results were shared from its FT825 and FT522 programs, reinforcing the company's commitment to innovative therapies.
Read more →FATEMartin Hosking, Ph.D.
Martin Hosking, Ph.D., is the Head of Research at Fate Therapeutics, focusing on iPSC-derived immune cell therapies for cancer and autoimmune diseases. With over 20 years of experience, he has contributed significantly to the field through research and patents. He holds both a Ph.D. and B.S. from UC Irvine.
Read more →FATE▼ -8%on this newsshared move
Victor Hong, M.B.A., M.P.H.
Victor Hong has been appointed as Vice President, Global Operations Lead at Fate Therapeutics, where he will oversee program strategy and execution. He previously held significant roles at BMS and Celgene, focusing on hematology strategy and business planning. With over 20 years of experience in the industry, he brings a wealth of knowledge and expertise.
Read more →FATEMichelle Greenman
Michelle Greenman has been appointed Vice President of Regulatory Affairs at Fate Therapeutics. She will oversee global regulatory affairs, including strategy and submission management. Greenman brings a wealth of experience from her previous roles at various biotechnology firms and holds a degree in Biology along with a graduate certificate in Regulatory Science.
Read more →FATEKate Duvall
Kate Duvall has been appointed as the Corporate Controller at Fate Therapeutics, where she will manage accounting operations, financial reporting, and compliance. She previously worked as an auditor at Ernst & Young, specializing in life sciences and healthcare. Duvall is a Certified Public Accountant and holds a degree in accounting from the University of San Diego.
Read more →FATERyan Douglas, M.B.A.
Ryan Douglas has been appointed as Senior Director of Investor Relations & Business Development at Fate Therapeutics. He will manage corporate communications and drive strategic partnerships to enhance the company's growth. With over twenty years of experience in finance, Douglas previously served at Exagen Inc., where he improved investor relations and capital markets strategy.
Read more →FATE▼ -8.1%on this news· ran to -25% by day 3shared move
Yu Cai, J.D., Ph.D.
Yu Cai, J.D., Ph.D., is the Head of Intellectual Property at Fate Therapeutics. With nearly ten years of experience, she manages all aspects of IP protection and strategy. Dr. Cai has a strong academic background, holding degrees in Plant Sciences, Biochemistry, and Law, and previously practiced IP law in the biotechnology sector.
Read more →FATE▼ -9.6%on this news· ran to -28% by day 3shared move
Noreen Blanchett, J.D.
Noreen Blanchett has been appointed as Vice President and Deputy General Counsel at Fate Therapeutics. In her role, she will oversee daily legal operations and provide counsel across the organization. Previously, she served as Associate General Counsel at SeaSpine, Inc. Blanchett holds a J.D. from UCLA and a B.A. in Applied Mathematics from UC Berkeley.
Read more →FATEFate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
Fate Therapeutics has presented promising Phase 1 clinical data for its FT819 CAR T-cell therapy targeting systemic lupus erythematosus. In the initial cohort of three patients, all experienced significant B-cell depletion and no serious adverse events. The first patient is in clinical remission and has successfully discontinued all previous immunosuppressant treatments. The company plans to expand dosing and continue development based on these positive initial outcomes.
Read more →FATEFate Therapeutics Announces Leadership Transition Bob Valamehr, Ph.D. MBA, To Become President and CEO
Fate Therapeutics announced a leadership transition with Bob Valamehr, Ph.D. MBA, set to become President and CEO on January 1, 2025. He will succeed Scott Wolchko, who will retire after 10 years of guiding the company in developing iPSC-derived cellular immunotherapies. The company continues to focus on its innovative platform, with ongoing clinical trials, including FT819 for systemic lupus erythematosus. Wolchko will remain a strategic advisor, providing experienced guidance during this transition.
Read more →FATEFate Therapeutics Announces Leadership Transition
Fate Therapeutics announced a leadership transition, with current President of R&D, Bob Valamehr, set to assume the role of President and CEO starting January 1, 2025, following Scott Wolchko's retirement. Wolchko has led the company for ten years, overseeing the development of innovative iPSC-derived immunotherapies for cancer and autoimmune diseases. Valamehr's extensive experience in the iPSC platform positions him well to continue advancing the company's clinical pipeline, including product candidate FT819 for systemic lupus erythematosus.
Read more →FATE▲ +10.7%on this news· ran to +31% by day 1shared move
Fate Therapeutics to Present at Upcoming December Investor Conferences
Fate Therapeutics, Inc. will present at two upcoming investor conferences in December 2024. The first is Citi's 2024 Global Healthcare Conference in Miami on December 3, followed by Piper Sandler's 36th Annual Healthcare Conference in New York on December 4. The presentations will include panel discussions and a fireside chat, accessible via live webcast on the company's website.
Read more →FATE▲ +12.4%on this news
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Fate Therapeutics has presented initial data from its Phase 1 study of FT522, a CD19-targeted CAR NK cell product, during the ACR Convergence. The data indicates a favorable safety profile, with initial responses observed in patients with relapsed/refractory B-cell lymphoma. FT522 shows promise not only for its potential effectiveness but also for its ability to persist functionally without the need for conditioning chemotherapy. The company is also beginning a Phase 1 study of FT522 for B-cell mediated autoimmune diseases.
Read more →FATE▲ +12.4%on this news
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
Fate Therapeutics has presented promising initial results from a Phase 1 autoimmunity study involving its FT819 CAR T-cell therapy for systemic lupus erythematosus (SLE). A 27-year-old patient with active lupus nephritis achieved clinical remission without the need for immunosuppressive therapies after treatment with FT819. The safety profile was favorable, with no severe adverse events reported, and an immune reset was observed in the patient's B cell compartment. This study highlights the potential of FT819 as a significant therapeutic advancement for lupus patients.
Read more →FATE▼ -7%on this news· ran to -21% by day 3
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatmen
Fate Therapeutics reported promising developments in its third quarter 2024 financial results, highlighting advancements in their CAR T-cell product candidates. Initial Phase 1 clinical data for FT819 and FT522 showcases favorable safety profiles and the potential for effective treatment options in autoimmune diseases and solid tumors. Additionally, they have a strong cash position, which supports ongoing clinical trials and further research initiatives. The company is actively pursuing enrollment for new treatment arms and anticipates presenting initial data at upcoming medical conferences.
Read more →FATE▲ +5.8%on this newsshared move
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Fate Therapeutics presented promising results for its CAR T-cell product candidate FT825/ONO-8250, targeting HER2 to treat advanced solid tumors, at the 2024 SITC Annual Meeting. Initial Phase 1 trial data demonstrated a favorable safety profile with no dose-limiting toxicities or serious adverse events noted. The product showed significant CAR T-cell expansion and maintained an activated state post-treatment. The novel H2CasMab-2 antigen binding domain may enable selective targeting of cancer cells while minimizing effects on healthy tissues.
Read more →FATE▼ -5.1%on this newsshared move
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
Fate Therapeutics recently presented promising preclinical data for FT836, a multiplexed-engineered CAR T-cell candidate targeting MICA and MICB proteins, at the 2024 SITC Annual Meeting. This innovative therapy aims to address common challenges in CAR T-cell treatment for solid tumors. With the incorporation of Sword & Shield technology, FT836 shows a potential for durable anti-tumor effects without the requirement for conditioning chemotherapy. The presented data indicates strong activity across a range of cancers, providing optimism for the future of this treatment approach.
Read more →FATEFate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company, will present at the 2024 Cantor Global Healthcare Conference on September 19, 2024, in New York. The company focuses on developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. The presentation is expected to highlight their proprietary technologies and product pipeline, which includes advanced NK and T-cell candidates.
Read more →FATEFate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates Enrollment Ongoing with FT819 1XX CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Single-agent Cyclophosphamide Included as
Fate Therapeutics has announced positive developments in its multiple ongoing Phase 1 clinical trials for CAR T-cell and CAR NK cell therapies. The company reports successful initial treatments including the first patient for the FT522 candidate, progressing towards further studies without conditioning chemotherapy. Financially, Fate holds a substantial cash reserve projected to last through the end of 2026. Data presentations are expected in the second half of 2024, fostering optimism in their pipeline targeting autoimmune conditions and solid tumors.
Read more →FATEFate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors San Diego, CA
Fate Therapeutics, Inc. has announced the appointment of Dr. Neely Mozaffarian to its Board of Directors, effective immediately. Dr. Mozaffarian brings over 20 years of experience in immunology, focusing on systemic lupus erythematosus. The company recently treated its first patient in a Phase 1 study of FT819, an iPSC-derived cell product, with no adverse effects reported. Fate Therapeutics aims to enhance its clinical development strategy through Dr. Mozaffarian's expertise as it expands its efforts in autoimmune disease treatments.
Read more →FATEFate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics announced its participation in the 2024 Jefferies Global Healthcare Conference, scheduled for June 5, 2024, in New York City. The company specializes in developing cellular immunotherapies derived from induced pluripotent stem cells (iPSCs) targeting cancer and autoimmune diseases. The presentation will highlight their proprietary iPSC product platform and pipeline, which includes innovative natural killer (NK) and T-cell therapies.
Read more →FATE▲ +5.4%on this news
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819
Fate Therapeutics has shared its financial results and business progress for Q1 2024, noting significant advancements in clinical studies. The company successfully treated its first lupus patient with the FT819 CAR T-cell therapy and initiated patient enrollment for FT522 CAR NK cell therapy without conditioning chemotherapy. Furthermore, the first patient was treated with the FT825 CAR T-cell product in solid tumors. Fate Therapeutics currently holds $391 million in cash, reinforcing its capacity for ongoing and future clinical development.
Read more →FATE▲ +5.4%on this news
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program Pre-treatment Sample of Patient s Blood Showed Rapid and Potent Depletion of CD19+ B Cells i
Fate Therapeutics has reported the successful treatment of its first patient with systemic lupus erythematosus in a Phase 1 study of the FT819 CAR T-cell program. This milestone is accompanied by preliminary data indicating effective depletion of CD19+ B cells, which could signify a novel approach to addressing B cell-mediated autoimmune diseases. The company aims to leverage its off-the-shelf cell therapies to enhance patient access while minimizing adverse effects commonly associated with traditional CAR-T therapies. This announcement was made alongside the presentation of additional translational data at the ASGCT annual meeting.
Read more →FATEFT522: A CAR NK Cell with the Unique Ability to Target Multiple Pathogenic Cell Types and Circumvent Lympho-conditioning in Systemic Autoimmunity
The article discusses FT522, a CAR NK cell designed to target multiple pathogenic cell types and avoid lympho-conditioning in systemic autoimmunity. However, it provides minimal details on the cell's performance or clinical implications. The content primarily focuses on website privacy and cookie usage rather than the biopharma topic.
Read more →FATEFT819-102: Clinical Translation of Off-the-Shelf TCR-less CD8αβ+ anti-CD19 CAR-T Cells for The Treatment of B cell-mediated Autoimmune Disorders
The article discusses the clinical translation of FT819-102, an off-the-shelf TCR-less CD8αβ+ anti-CD19 CAR-T cell therapy aimed at treating B cell-mediated autoimmune disorders. It highlights the potential of this innovative therapy but lacks specific details regarding outcomes or current trial status.
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
Fate Therapeutics, Inc. will host a conference call on May 9, 2024, to discuss its first quarter 2024 financial results and operational updates. The call will highlight the company's FT819 and FT522 programs, which are focused on treating autoimmune diseases. This event coincides with their presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting, emphasizing their commitment to advancing cellular immunotherapies. Investors can access the live event via their website, with an archived version available later.
Read more →FATEFate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
Fate Therapeutics, Inc. has announced that it will present preclinical data on its CD19-targeted CAR NK cell product candidate, FT522, at the upcoming ASGCT Annual Meeting. This late-breaking abstract highlights FT522's ability to deplete B-cells in donors with systemic lupus erythematosus, without requiring conditioning chemotherapy. The innovative alloimmune defense receptor technology incorporated into FT522 aims to enhance its therapeutic efficacy. The presentation is scheduled for May 9, 2024, in Baltimore, Maryland.
Read more →FATEFate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fate Therapeutics has announced the presentation of FT819 proof-of-concept data at the upcoming ASGCT Annual Meeting, scheduled for May 7-11, 2024. The data will focus on key therapeutic mechanisms for autoimmune diseases, particularly B cell-mediated conditions, from its ongoing Phase 1 study in relapsed/refractory B-cell malignancies. Additionally, the company has initiated patient enrollment for a Phase 1 study targeting moderate-to-severe systemic lupus erythematosus (SLE) with its off-the-shelf CAR T-cell therapy, FT819. This initiative demonstrates the company's commitment to advancing innovative iPSC-derived therapies for patients with complex diseases.
Read more →FATEFate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Fate Therapeutics, Inc. has announced its participation in the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 10, 2024. The presentation will highlight the company's innovative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies aimed at treating cancer and autoimmune disorders. Attendees can access a live webcast of the presentation on the company's website following the event. Fate Therapeutics is noted for its leadership in developing engineered iPSC lines and off-the-shelf cellular products.
Read more →FATEFate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement San Diego, CA
Fate Therapeutics has announced the pricing of a $100 million underwritten offering and a concurrent private placement. The offering includes 14,545,454 shares priced at $5.50 each, with participation from several institutional investors. The company plans to utilize the proceeds to fund clinical trials, manufacturing expenses, and general corporate needs. The deal is expected to close around March 21, 2024, subject to customary conditions.
Read more →FATE▲ +9.2%on this newsshared move
Fate Therapeutics to Present at Upcoming March Investor Conferences
Fate Therapeutics will participate in several investor conferences in March 2024, showcasing its commitment to engaging with investors. The company will be involved in various formats, including industry panels and 1x1 meetings, across multiple locations such as Boston and Miami. This participation aims to highlight Fate's innovative pipeline of iPSC-derived cellular immunotherapies targeting cancer and autoimmune disorders.
Read more →FATEFate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Ery
Fate Therapeutics reported its financial results for Q4 and full year 2023, highlighting significant advancements in its clinical programs. The company was awarded a $7.9 million grant to support a Phase 1 study of its FT819 CAR T-cell therapy for systemic lupus erythematosus. They initiated the first patient treatment in the Phase 1 study of FT522, a CAR NK cell therapy also targeting B-cell malignancies. Despite a strong cash position of $316 million, the company reported only $1.7 million in revenues in Q4, against substantial operating expenses.
Read more →FATE▲ +9.1%on this news
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
Fate Therapeutics, Inc. plans to host a conference call and live audio webcast on February 26, 2024, to report its fourth quarter and full year 2023 financial results. The company focuses on first-in-class cellular immunotherapies developed from induced pluripotent stem cells (iPSCs) for cancer and autoimmune disorders. This event will be accessible via their website, providing investors with updates on the company's activities and financial performance. Fate Therapeutics is based in San Diego, CA, and is actively involved in clinical development.
Read more →FATE▲ +9.3%on this news
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
Fate Therapeutics has announced the enrollment for a Phase 1 clinical trial of FT825 / ONO-8250, a novel CAR T-cell therapy targeting HER2-expressing advanced solid tumors. The trial, conducted in partnership with Ono Pharmaceutical, aims to evaluate the safety, tolerability, and anti-tumor activity of the treatment. FT825 / ONO-8250 incorporates advanced synthetic controls for improved targeting and efficacy in difficult-to-treat cancers. If successful, this therapy could provide new options for patients with limited treatments available.
Read more →FATE▲ +11.7%on this news· ran to +31% by day 3
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics announced the grant of stock options to a new employee, which includes the option to purchase 350,000 shares at an exercise price of $2.28. This grant is part of the company's Amended and Restated Inducement Equity Plan and complies with Nasdaq Listing Rule 5635(c)(4). Fate Therapeutics focuses on developing innovative induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune disorders, bolstered by a robust intellectual property portfolio.
Read more →FATEFate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to
Fate Therapeutics, Inc. announced strong advancements in its pipeline during the third quarter of 2023, including the initiation of patient enrollment in a Phase 1 study for its FT522 CAR NK cell program targeting B-cell lymphoma. The FDA has cleared IND applications for multiple CAR T-cell programs, expanding opportunities in oncology and autoimmunity. The company reported $350 million in cash, which should sustain its operations into the second half of 2025; however, it also recorded a modest revenue of $1.9 million and significant operating expenses of $53.2 million during the quarter.
Read more →FATE▲ +5%on this newsshared move
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Fate Therapeutics, Inc. is under investigation by Bragar Eagel & Squire, P.C. for potential claims following a class action lawsuit. The investigation is focused on whether the board breached fiduciary duties after a series of negative developments, including the termination of its collaboration with Janssen and significant layoffs. The class action lawsuit alleges failure to disclose material information regarding these critical events. Consequently, long-term stockholders are encouraged to reach out for more information regarding their rights and potential claims.
Read more →FATE▼ -7.2%on this news
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
Fate Therapeutics, a clinical-stage biopharmaceutical company, will hold a conference call and live audio webcast on November 8, 2023, to report its third quarter financial results and provide a corporate update. The company's focus is on developing first-in-class iPSC-derived cellular immunotherapies targeting cancer and autoimmune disorders. Details about the event can be found on their website, including registration and access to archived material post-event.
Read more →FATEFate Therapeutics to Present at Upcoming September Investor Conferences
Fate Therapeutics, Inc. has announced its participation in two upcoming investor conferences scheduled for early September 2023. The company will attend Citi's 18th Annual BioPharma Conference and the Wells Fargo 2023 Healthcare Conference, where it will engage in investor meetings and a fireside chat. These events demonstrate Fate's commitment to connecting with investors and fostering relationships in the biopharmaceutical community.
Read more →FATEFate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to
Fate Therapeutics recently released its financial results for the second quarter of 2023, highlighting ongoing advancements in its CAR NK cell and T-cell programs. The clinical-stage biopharmaceutical company reported a strong cash position of $385 million, which is expected to sustain operations into 2025. Notably, the FDA has approved the IND application for its FT522 product, which is currently entering its Phase 1 trials. Despite this progress, the company's revenue remains low at $0.9 million, with high operating expenses of $63.5 million, prompting cautious outlooks.
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
Fate Therapeutics, Inc. will host a conference call on August 8, 2023, at 5:00 PM ET to discuss its second quarter 2023 financial results and provide corporate updates. This event will be accessible via a live audio webcast on the company's website. Fate Therapeutics focuses on developing innovative cellular immunotherapies using induced pluripotent stem cells for cancer and autoimmune disorders, establishing a strong position within its industry.
Read more →FATE▲ +5.2%on this news
FATE THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
Kahn Swick & Foti, LLC has launched an investigation into Fate Therapeutics, Inc. to determine if its executives breached fiduciary duties to shareholders. This follows a significant termination of their collaboration with Janssen Biotech, which included a $50 million payment and potential future earnings exceeding $3 billion. The investigation is compounded by a pending securities class action lawsuit concerning allegations of undisclosed material information. Additionally, the company has laid off employees and ceased multiple cancer programs, raising concerns about its operational stability.
Read more →FATEFate Therapeutics to Present at Upcoming June Investor Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences: the Jefferies Healthcare Conference on June 7, 2023, and the Goldman Sachs Global Healthcare Conference on June 13, 2023. The company focuses on first-in-class induced pluripotent stem cell-derived cellular immunotherapies aimed at treating cancer and autoimmune disorders. The event participation reflects the company’s efforts to engage investors and share updates on their innovative therapies.
Read more →FATE▲ +6.8%on this news
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favo
Fate Therapeutics has reported its financial results for the first quarter of 2023, highlighting ongoing dose escalation in its Phase 1 FT819 CAR T-cell study demonstrating a favorable safety profile and complete responses in aggressive large B-cell lymphoma. The company has a robust cash position of $426 million to support its operations into the second half of 2025. Additionally, it is advancing several innovative programs, including FT576 for multiple myeloma and FT522 for B-cell lymphoma, while strategically focusing on its most promising pipeline assets following a restructuring, including a workforce reduction post-collaboration termination with Janssen Biotech.
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
Fate Therapeutics, Inc. has announced a conference call and live audio webcast scheduled for May 3, 2023, to report its first quarter 2023 financial results. The company is focused on induced pluripotent stem cell-derived immunotherapies for cancer and autoimmune disorders. They emphasize their leadership in creating advanced iPSC lines and off-the-shelf cell products, which are critical for patient treatment. The event will be accessible through their website, indicating commitment to investor engagement.
Read more →FATEFATE FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys, Mar. 22nd Deadline Pending in Securities Class Action
Hagens Berman is urging investors in Fate Therapeutics, Inc. to report losses following a class action lawsuit related to misleading statements concerning a collaboration with Janssen Biotech. The lawsuit claims that Fate overstated the potential benefits and sustainability of the collaboration, which has now been terminated, leading to a significant drop in share price and workforce reduction. The lead plaintiff deadline for filing claims is March 22, 2023, as investors seek legal recourse for their financial losses related to this alleged securities fraud.
Read more →FATEFATE IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
Rosen Law Firm is urging investors of Fate Therapeutics, Inc. (NASDAQ: FATE) to secure legal counsel before March 22, 2023, in light of a pending securities class action lawsuit. The suit alleges that the company made misleading statements regarding its collaboration with Janssen Biotech, potentially overstating the sustainability and future revenue reliability of their partnership. Affected investors are encouraged to join the class action to seek compensation without upfront costs. The Rosen Law Firm emphasizes the importance of selecting qualified legal representation, given their established track record in securities litigation.
Read more →FATEFATE 6-DAY DEADLINE ALERT: Hagens Berman Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys Before Mar. 22nd Deadline in Securities Class Action
Hagens Berman is urging investors of Fate Therapeutics, Inc. (FATE) who suffered significant losses to contact their attorneys by March 22nd, in light of a securities fraud class action. The litigation stems from claims that Fate misled investors about the viability of its collaboration with Janssen Biotech regarding cancer treatment. After the collaboration was terminated on January 5, 2023, due to an unsuccessful proposal for revised terms, Fate's stock plummeted by over 60%. The company has also announced significant layoffs, further impacting its outlook.
Read more →FATE▼ -8.8%on this news
Fate Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 22, 2023 deadline
Fate Therapeutics, Inc. is facing a lawsuit from investors who purchased its securities between April 2020 and January 2023, stemming from a significant drop in share price following the termination of a collaboration with Janssen Biotech. The lawsuit claims that the company misled investors about the viability of the partnership and failed to disclose critical information regarding future revenue sources. The Portnoy Law Firm is offering assistance to affected investors looking to recover their losses.
Read more →FATEFate Therapeutics, Inc. (FATE) Lead Deadline Approaching: Contact Robbins LLP for Information Regarding the Class Action against Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is currently facing a class action lawsuit filed by shareholders for alleged misrepresentation of the impact from its collaboration with Janssen Biotech. The lawsuit pertains to claims that Fate misled investors about the sustainability and profitability of the collaboration, which has now been terminated. Following the termination disclosed on January 5, 2023, Fate's stock experienced a significant drop, falling over 61%. Additionally, the company plans to reduce its workforce and end several programs as a consequence of the financial fallout.
Read more →FATEFate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initia
Fate Therapeutics reported its financial results for the fourth quarter and full year 2022, ending with approximately $475 million in cash. The company outlined significant advancements in its pipeline, including the initiation of multi-dose treatment cohorts for its FT576 program for multiple myeloma and updates on the FT819 and FT522 programs for B-cell malignancies. Plans for several IND submissions in 2023 underscore the company's commitment to expanding its offerings in cellular immunotherapies. The preliminary clinical data reflects encouraging safety profiles and therapeutic responses in early-stage trials.
Read more →FATEFate Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm
Fate Therapeutics Inc. is indirectly mentioned as the context involves the Portnoy Law Firm investigating ESS Tech for possible securities fraud. The investigation arises from allegations made by Grizzly Research that ESS Tech misled investors about its partnership with Energy Storage Industries Asia Pacific. This partnership was claimed to be fabricated, contributing to a decline in ESS Tech's stock price. Investors affected by this situation are encouraged to contact the firm for potential class action claims.
Read more →FATEFATE SHAREHOLDER NOTICE: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed
Fate Therapeutics has been subjected to a securities fraud class action following its termination of a collaboration agreement with Janssen Biotech. The lawsuit alleges that the company misrepresented the viability of the agreement and the financial prospects linked to it, resulting in significant investor losses. Following the announcement, Fate experienced a drastic drop in its stock price and plans to reduce its workforce significantly. Legal firms are urging affected investors to come forward as the situation develops.
Read more →FATEFate Therapeutics, Inc. (FATE) Class Action: Contact Robbins LLP for Information Regarding the Class Action and Lead Plaintiff Deadline
Fate Therapeutics, Inc. is facing a class action lawsuit filed by investors who acquired shares between April 2, 2020, and January 5, 2023, claiming that the company misrepresented the impact of its collaboration agreement with Janssen Biotech. The lawsuit comes after Fate terminated the agreement, resulting in a 61.45% drop in stock price. The termination has led to a reduction in workforce and discontinuation of various cancer programs, impacting the company's long-term profitability. Shareholders interested in acting as lead plaintiffs have until March 22, 2023, to file their papers.
Read more →FATEFATE INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed
Fate Therapeutics, Inc. is facing a securities class action due to allegations of misleading investors regarding its collaboration with Janssen Biotech. The firm reportedly overstated the viability of the agreement, which has now been terminated, leading to significant layoffs and a steep decline in stock value. The lawsuit focuses on investor losses linked to the company’s misrepresentation of potential revenue from the collaboration. Hagens Berman, the law firm leading the charge, is seeking to represent affected investors.
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
Fate Therapeutics, a clinical-stage biopharmaceutical company, announced it will host a conference call on February 28, 2023, to report its fourth quarter and full year 2022 financial results. The call will be accessible via an audio webcast that can be found on the company's website. Fate Therapeutics specializes in developing advanced cellular immunotherapies, utilizing its proprietary induced pluripotent stem cell technology. This event will also provide a corporate update to shareholders.
Read more →FATEFate Therapeutics, Inc. (FATE) Class Action Alert: Contact Robbins LLP for Information Regarding the Class Action Against Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is facing a class action lawsuit filed by a shareholder due to alleged violations of the Securities Exchange Act of 1934. The lawsuit claims the company misrepresented the sustainability of its collaboration with Janssen Biotech, which was expected to significantly contribute to its long-term profitability. Following the termination of this collaboration, Fate revealed plans to downsize and discontinue certain cancer treatment programs, resulting in a severe drop in its stock price. Investors are urged to consider their options before the lead plaintiff deadline on March 22, 2023.
Read more →FATE▲ +6.9%on this news
FATE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced the potential for a class action lawsuit against Fate Therapeutics, Inc. for alleged violations of the Securities Exchange Act. Investors who acquired Fate's securities between April 2020 and January 2023 may seek to be appointed as lead plaintiff. The lawsuit stems from claims that the company misrepresented the sustainability of its collaboration with Janssen Biotech, which has now been terminated, leading to significant financial losses for investors. Following this announcement, Fate's stock value plummeted, creating further concerns about its future profitability and operational capacity.
Read more →FATEFATE CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
Hagens Berman has announced a class action lawsuit against Fate Therapeutics, Inc. following substantial losses faced by investors. The lawsuit centers on misleading statements related to Fate's collaboration with Janssen Biotech for developing cancer treatment products. Following the termination of this partnership on January 5, 2023, Fate revealed that it would scale down operations and cut its workforce significantly, leading to a dramatic drop in share prices. Investors with significant losses during the class period are encouraged to contact the firm's attorneys for legal assistance.
Read more →FATE▲ +11.7%on this newsshared move
Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is facing a class action lawsuit filed by shareholders for alleged misrepresentation regarding the impact of its collaboration agreement with Janssen Biotech. The lawsuit claims that Fate overstated the sustainability of the collaboration, which was backed by a $50 million upfront payment and potential future earnings. On January 5, 2023, Fate announced the termination of this collaboration, causing a significant decline in its stock price and the reduction of its workforce. The company also disclosed the discontinuation of multiple clinical programs, adding to concerns regarding its future profitability.
Read more →FATEFate Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 22, 2023 deadline.
Fate Therapeutics, Inc. is facing a lawsuit due to alleged misleading statements made before the announcement of the termination of its collaboration agreement with Janssen Biotech. This termination, expected to generate $3 billion, reportedly led to a significant drop in the company's share price. Investors who purchased Fate securities between April 2, 2020, and January 5, 2023, are encouraged to contact The Portnoy Law Firm to discuss potential recovery of their losses. The lawsuit claims that certain revenue sources were not reliably disclosed to investors prior to the announcement.
Read more →FATEFATE INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
Fate Therapeutics, Inc. is facing legal scrutiny following the termination of its collaboration with Janssen Biotech, leading to significant financial losses for investors. The company announced that it would wind down all collaboration activities with Janssen in Q1 2023 and reduce its workforce by approximately 60%. This news resulted in a drastic drop in share prices and prompted multiple analyst downgrades. Legal firm Hagens Berman is encouraging affected investors to come forward regarding possible securities law violations.
Read more →FATE▼ -61.5%on this news
Fate Therapeutics Shareholder Investigation: Submit Your Losses to Johnson Fistel
Johnson Fistel, LLP is investigating Fate Therapeutics, Inc. for potential violations of securities laws due to misrepresentation or failure to disclose adverse information to investors. The investigation was prompted by recent announcements from Fate, including the decline of a proposal from Janssen Biotech for a collaboration that would have advanced two product candidates. Following this news, the company's stock saw a dramatic decline of over 50%, prompting concerns over shareholder losses.
Read more →FATE▼ -61.5%on this news
FATE Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Potential Securities Claims Against Fate Therapeutics, Inc.
Wohl & Fruchter LLP is investigating Fate Therapeutics, Inc. for potential violations of federal securities laws after the company terminated its collaboration with Janssen Biotech. The announcement led to a nearly 50% drop in FATE's stock price in after-hours trading. The investigation stems from concerns that Fate may have misled investors concerning the terms and future of the agreement with Janssen, which the company previously promoted as a key partnership.
Read more →FATEFate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives Ended 2022 with Approximately $475 Million in Cash, Cash Equiva
Fate Therapeutics announced the termination of its collaboration agreement with Janssen, which will result in the winding down of their joint activities. Despite this setback, the company retains a solid financial position with approximately $475 million to support operations through 2025. Fate is refocusing on advancing its pipeline of second-generation CAR NK cell therapies while discontinuing certain product candidates. The decision includes substantial workforce reductions and is aimed at prioritizing innovative therapies for hematologic malignancies and autoimmune disorders.
Read more →FATEFate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, presented preclinical data of several novel strategies des
Read more →FATE▼ -14.3%on this news· ran to -25% by day 3shared move
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Interim Phase 1 Dose-escalation Data Indicate Favorable Safety Profile with Complete Responses in Heavily Pre-treated Pati
Read more →FATE▼ -14.3%on this news· ran to -25% by day 3shared move
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data under Janssen Collaboration with FT555 GPRC5D-targeted Product Candidate Demonstrate
Read more →FATEFate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Po
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical
Read more →FATEFate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of F
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL
Read more →FATEFate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell Lymphoma Preclinical Data of FT555 GPRC5D-targeted CAR NK Cell Collaboration Candidat
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced tha
Read more →FATEFate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
SAN DIEGO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present clinical and
Read more →FATEFate Therapeutics to Participate at Upcoming September Investor Conferences
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced th
Read more →FATE▲ +7.1%on this news
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive B
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced tha
Read more →FATEFate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial O
Read more →FATE▼ -5.7%on this newsshared move
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies ONO to Contribute Novel Binding Domains for a Second
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partner
Read more →FATEFate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced tha
Read more →FATE▼ -11.1%on this news
Fate Therapeutics to Present at Upcoming May Investor Conferences
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that
Read more →FATE▲ +6.6%on this news· ran to -22% by day 3shared move
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL FT596+R-CHOP Clinical Protocol for
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL FT596+R-CHOP Clinical Protocol for First-line Investigation to be Submitted to FDA in 2Q22 F
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results
SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced th
Read more →FATEFate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose f
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69%
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced tha
Read more →FATEFate Therapeutics to Present at Upcoming February Investor Conferences
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced tha
Read more →FATEFate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Antigen Binding Domain of FT536 has been Shown
Read more →FATEFate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refracto
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL 6 of 10 Patients Na ve to Treatment with Autologou
Read more →FATEFate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients Achieve Objective Response with Single Dose of FT596 at 90 Million and 300 Million Cell Dose; 1
Read more →FATEFate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting
SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event
Read more →FATEFate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference
Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with can
Read more →FATEFate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting
FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FA
Read more →FATEFate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data o
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 fo
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company
Read more →FATEFate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentation
Read more →FATEFate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today the publication of preclinical data demo
Read more →FATE▼ -5.9%on this news· ran to -26% by day 1
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab Following Autologous CD19 CAR T-cell Therapy 8 of 11 Patients in FT516
Read more →FATEFate Therapeutics Appoints Yuan Xu to its Board of Directors San Diego, CA
Fate Therapeutics Appoints Yuan Xu to its Board of Directors San Diego, CA August 4, 2021 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appoi
Read more →FATEFate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-der
Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate De
Read more →FATEFate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate Three Dosing Regimens of FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO, A
Read more →FATEFate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight i
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference call and live au
Read more →FATEFate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chie
Read more →FATEFate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting
8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell Therapy Favorable FT516 Safety Profile Was Observed; No FT516-related Serious Adv
Read more →FATEFate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia
4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow 2 Patients in Second Dose Escalation Cohort of FT516 Monotherapy Study Continued in Remission without Further Therapeutic Intervention at 6-month Foll
Read more →FATEFate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021 Phase 1 Data from FT516 and
Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021 Phase 1 Data from FT516 and FT538 Programs in Relapsed / Refractory Acute Myeloid Leuk
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company
Read more →FATEFate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting
Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline Company to Host Investor Event on May 13 to Highlight Interim Phase 1 Clinical Data from the Company’s FT516 and FT538 Programs for Relapsed / Refractory AML SAN DIEGO, April 27, 2021 (GLOBE N
Read more →FATEFate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service San Diego, CA
Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service San Diego, CA - March 25, 2021 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies fo
Read more →FATEFate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Co
Read more →FATEFate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company
Read more →FATEFate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announ
Read more →FATEFate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announ
Read more →FATEFate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock SAN DIEGO, CA January 4, 2021 (GLOBE NEWSWIRE) Fate Therapeutics, Inc. (the Company or Fate Therapeutics ) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developmen
Read more →FATEFate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma
Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells Deepening of Response Observed with FT596 Retreatment Duration of Response Comparable to FDA-approved Autologous CAR T-cell Therapy for Patients with Partia
Read more →FATEFate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma
3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response No Observed Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Host D
Read more →FATEFate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual
Read more →FATEFate Therapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following
Read more →FATEFate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting
Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event on Friday, December 4 SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmac
Read more →FATEFate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma FT5
Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma FT596 Phase 1 Study Expanded to Include Chronic Lymphocytic L
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company will host a confer
Read more →FATEFate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
SAN DIEGO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that five abstracts for the Company
Read more →FATEFate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will participate i
Read more →FATEFate Therapeutics Announces September Investor Events
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following
Read more →FATEFate Therapeutics Appoints Edward Dulac as Chief Financial Officer San Diego, CA
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer San Diego, CA - August 19, 2020 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disor
Read more →FATEFate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated wi
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma
Read more →FATEFate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Sc
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confer
Read more →FATEFate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies
License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients Preclinical Data Published in the Journal Nature Biotechnology Demonstrate Allogeneic CAR T Cells Overcome Immune Rejection and Exhibit Du
Read more →FATEFate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) --
Read more →FATEFate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announ
Read more →FATEFate Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announ
Read more →FATEFate Therapeutics Announces Proposed Public Offering of Common Stock
Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, June 8, 2020 (GLOBE NEWSWIRE) Fate Therapeutics, Inc. (the Company or Fate Therapeutics ) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellul
Read more →FATEFate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy
Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the-shelf NK Cell Product Candidate Derived from Clonal Master iPSC Line Engineered with Th
Read more →FATEFate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates First Patient
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates First Patient Treated with FT596, the First-ever Cellular Immunotherapy
Read more →FATEFate Therapeutics Announces Changes to its Board of Directors San Diego CA
Fate Therapeutics Announces Changes to its Board of Directors San Diego CA - May 5, 2020 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, toda
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results
SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confere
Read more →FATEFate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting
Program Incorporates New CAR Constructs Designed to Specifically Target the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Binding Domains Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Exclusive L
Read more →FATEFate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies Collaboration leverages Company's iPSC product platform and Janssen's proprietary tumor-targeting
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies Collaboration leverages Company's iPSC product platform and Janssen's proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell produ
Read more →FATEFate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient has been tr
Read more →FATEFate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook Reported Initial Clinical Data from FT500 Phase 1 Study in Advanced Solid Tumors, Supporting Safety and Tolerabil
Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook Reported Initial Clinical Data from FT500 Phase 1 Study in Advanced Solid Tumors, Supporting Safety and Tolerability of Multi-dose Treatment Paradigm for Off-the-shelf, iP
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results
SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confer
Read more →FATEFate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood
FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies Published Preclinical Data Demonstrate iPSC-derived NK Cells Engineered with High-affinity, Non-cleavable CD16 Enhance the Efficacy of Antibo
Read more →FATEFate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting
FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of
Read more →FATEFate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy
FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma Combination of FT596 with Rituximab Shows Durable Tumor Clearance In Vivo in Preclinical Lymphoma Model Company Plans to Initiate Enrollment of First
Read more →FATEFate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs
No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs Reported in First 12 Patients Treated with FT500 for Advanced Soli
Read more →FATEFate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Sc
Read more →FATEFate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and C
Read more →FATEFate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting
FT596 Selected by ASH for Feature at “CAR-T and Beyond” Press Conference on December 7 Two Oral and Four Poster Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event at ASH on December 6 SAN DIEGO,
Read more →FATEFate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combi
Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with Rituximab Received FDA Clearance of IND Applic
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confer
Read more →FATEFate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies
SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has opened its cu
Read more →FATEFate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today annou
Read more →FATEFate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy
FT596 Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Anti-Tumor Functional Components Designed to Overcome CD19 Antigen Escape and Improve Durability of Response by Targeting Multiple Tumor-associated Antigens Off-the-Shelf Availability of FT596 En
Read more →FATEFate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and C
Read more →FATEFate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells
SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Patent and Trademark
Read more →FATEFate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress No FT500 DLTs Reported at Second Cell Dose Level in Monotherapy Arm or at First Cell Dose Level in Checkpoint Inhibitor
Fate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress No FT500 DLTs Reported at Second Cell Dose Level in Monotherapy Arm or at First Cell Dose Level in Checkpoint Inhibitor Combination Arm in Solid Tumor Study Successfully Complete
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2019 Financial Results
SAN DIEGO, July 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confer
Read more →FATEFate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors San Diego, CA
Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors San Diego, CA - July 17, 2019 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Read more →FATEFate Therapeutics to Present at the Jefferies 2019 Healthcare Conference
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Ch
Read more →FATEFate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress First-ever Patient Treated in U.S. with an iPSC-derived Cell Therapy Successfully Advances through Six-dose Treatment Cou
Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress First-ever Patient Treated in U.S. with an iPSC-derived Cell Therapy Successfully Advances through Six-dose Treatment Course No Dose-Limiting Toxicities or Serious Adverse Events
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confe
Read more →FATEFate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting
SAN DIEGO, April 24, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Fate scientists and collabora
Read more →FATEFate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development
SAN DIEGO, April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu, M.D. has
Read more →FATEFate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment
No Dose-Limiting Toxicities or Serious Adverse Events Reported following Three Once Weekly Doses of Universal, Off-the-Shelf NK Cell Product Candidate New Preclinical Data of Universal, Off-the-shelf, iPSC-derived NK Cell Product Candidates FT516 and FT596 Highlighted at 2019 AA
Read more →FATEFate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting
High-Throughput Selection of a Single Gene-Edited iPSC Enables Mass Production of Uniformly Engineered CAR T Cells FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrates Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus SAN DIEGO,
Read more →FATEFate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors San Diego, CA
Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors San Diego, CA - March 18, 2019 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Read more →FATEFate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Mar
Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Th
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confer
Read more →FATEFate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and C
Read more →FATEFate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation
SAN DIEGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Sarah Cooley, M.D., M.S., a le
Read more →FATEFate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day
SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Sc
Read more →FATEFate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell
FT516 Off-the-Shelf NK Cell Cancer Immunotherapy Cleared for Clinical Investigation by FDA Product Candidate Derived from Clonal Master iPSC Line Engineered with Novel CD16 Fc Receptor Clinical Trial to Evaluate Multi-dose Cycles of FT516 for Treatment of Hematologic Malignanci
Read more →FATEFate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new preclinical data on the Company’s ind
Read more →FATEFate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has secured an exclusive op
Read more →FATEFate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy
Company to Initiate First-ever U.S. Clinical Investigation of iPSC-derived Cell Product FT500 to be Featured in Oral Presentation on Monday, December 3 at ASH Annual Meeting SAN DIEGO, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bi
Read more →FATEFate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500
NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies and Solid Tumors Disease Control Shown in All Subjects Re-treated with Second Dose of NK100 No NK100-related Dose Limiting Toxicities Reported Submitted Data to FDA Demonstrating FT500 Master iPSC Bank
Read more →FATEFate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting
Three Oral and Four Poster Presentations Covering Product Pipeline Accepted for Presentation Company to Host Investor Event at ASH on November 30 SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedi
Read more →FATEFate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100 Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Co
Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100 Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical Completed $144M Commo
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and l
Read more →FATEFate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations
SAN DIEGO, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Wen Bo Wang, Ph.D., a leading expert in the m
Read more →FATEFate Therapeutics Announces Proposed Public Offering of Common Stock San Diego, CA
Fate Therapeutics Announces Proposed Public Offering of Common Stock San Diego, CA - September 20, 2018 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune
Read more →FATEFate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies Option-based Collaboration to Develop Two CAR T-Cell Product Candidates
Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate's Proprietary iPSC Product Platform San Diego,
Read more →FATEFate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming New Approach uses CRISPR-mediated Genome Activation for iPSC Generation San Diego, CA
Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming New Approach uses CRISPR-mediated Genome Activation for iPSC Generation San Diego, CA - September 13, 2018 - Fate Therapeutics, Inc. (NASDAQ: FATE), a cli
Read more →FATEFate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and C
Read more →FATEFate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress Treated 20 th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Stu
Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress Treated 20th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study Submitted First-of-Kind IND to FDA for Universal Off-th
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2018 Financial Results
SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confer
Read more →FATEFate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
SAN DIEGO, June 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Ch
Read more →FATEFate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies Dr. Michel Sadelain to Present Preclinical Data from iPSC-derived, TCR-less, CA
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies Dr. Michel Sadelain to Present Preclinical Data from iPSC-derived, TCR-less, CAR T-cell Collaboration at ASGCT 2018 San Diego, CA - May 1
Read more →FATEFate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Obse
Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in A
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conferen
Read more →FATEFate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Chief Scientific
Read more →FATEFate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program
Off-the-Shelf CAR T-cell Product Candidate Designed to Target CD19-positive Tumor Cells and to Overcome Antigen Escape Manufacture from Master iPSC Line Enables Mass Production and Broad Accessibility without Patient Restriction AACR Press Program to Begin Today at 8:30 a.m. Ce
Read more →FATEFate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018
SAN DIEGO, March 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today initial clinical data from the ongo
Read more →FATEFate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™
No Events of Cancer Relapse No ProTmune-related Serious Adverse Events Reported by Investigators SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular i
Read more →FATEFate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts i
Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow All Subjects in PROTECT Phase 1 Study of
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confere
Read more →FATEFate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy
SAN DIEGO, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the California Institute for Re
Read more →FATEFate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors
SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been trea
Read more →FATEFate Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President an
Read more →FATEFate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage
All Subjects Achieved Day 100 Relapse-free Survival All Incidents of Day 100 Acute GvHD Responded to Steroid Treatment Randomized, Controlled and Double-Blinded Phase 2 Stage of PROTECT Now Enrolling SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:
Read more →FATEFate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500
SAN DIEGO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that IND-enabling production
Read more →FATEFate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer
SAN DIEGO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been trea
Read more →FATEFate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies
Product Candidates to Incorporate Chimeric Antigen Receptor Construct Optimized for NK Cell Persistence and Anti-Tumor Activity Master Pluripotent Cell Lines Engineered with Chimeric Antigen Receptors to be used for Off-the-Shelf Targeted Natural Killer Cell Product Candidates
Read more →FATEFate Therapeutics to Present at the 2017 Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Ch
Read more →FATEFate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting
Subject in Dose Cohort 2 Achieves Morphologic Leukemia-free State at Day 14 No Dose Limiting Toxicities Reported SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of progra
Read more →FATEFate Therapeutics Reports Third Quarter 2017 Financial Results Clinical Data from First Subjects in VOYAGE Study of FATE-NK100 for Acute Myelogenous Leukemia to be Presented at SITC 2017 First-of-Kind iPSC-derived Cancer
Fate Therapeutics Reports Third Quarter 2017 Financial Results Clinical Data from First Subjects in VOYAGE Study of FATE-NK100 for Acute Myelogenous Leukemia to be Presented at SITC 2017 First-of-Kind iPSC-derived Cancer Immunotherapy Candidates FT500 and FT819 to be Featured i
Read more →FATEFate Therapeutics Announces Six Presentations at the 2017 ASH Annual Meeting
Oral Presentation Unveiling Generation of CD8αβ+ T Cells from Engineered Pluripotent Cell Line for Off-the-Shelf CAR T-Cell Cancer Immunotherapy Oral Presentation Highlighting GMP Production of iPSC-derived NK Cell Product Candidate FT500 to Support 1Q18 IND Filing Poster Prese
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results
SAN DIEGO, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confere
Read more →FATEFate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease
Independent Data Monitoring Committee Conducts Phase 1 Safety Review and Unanimously Recommends Opening of Phase 2 Enrollment First Seven Subjects Receiving ProTmune Clear Phase 1 Safety Objectives of Engraftment and Survival at Day 28 Phase 1 Day 100 Acute GvHD Data Expected t
Read more →FATEFate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development
SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has appointed Jim Beitel, M.B.A.
Read more →FATEFate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy
SAN DIEGO, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Patent and Trademark Office has issue
Read more →FATEFate Therapeutics Reports Second Quarter 2017 Financial Results First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent
Fate Therapeutics Reports Second Quarter 2017 Financial Results First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent Ovarian Cancer and in Advanced Solid Tumors with Monoclona
Read more →FATEFate Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Ch
Read more →FATEFate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100
Non-Clinical Studies Demonstrate Unique Anti-tumor Activity of Natural Killer Cell Product Candidate FDA Clears IND for FATE-NK100 in Ovarian Cancer SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company de
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2017 Financial Results
SAN DIEGO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confere
Read more →FATEFate Therapeutics Reports First Quarter 2017 Financial Results ProTmune PROTECT Safety Data Expected in Mid-2017 Launched First-in-Human Clinical Trial of FATE-NK100 for Acute Myelogenous Leukemia IND Cleared by FDA for
Fate Therapeutics Reports First Quarter 2017 Financial Results ProTmune PROTECT Safety Data Expected in Mid-2017 Launched First-in-Human Clinical Trial of FATE-NK100 for Acute Myelogenous Leukemia IND Cleared by FDA for FATE-NK100 with Monoclonal Antibody Therapy in Advanced S
Read more →FATEFate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administr
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results
SAN DIEGO, May 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conferen
Read more →FATEFate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Focus Session
SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it will host a Focus Session e
Read more →FATEFate Therapeutics to Present at the 5th Annual Cell & Gene Therapy Investor Day
SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and C
Read more →FATEFate Therapeutics Reports Fourth Quarter 2016 Financial Results First Subject Treated with ProTmune for GvHD Prevention IND Cleared by FDA for FATE-NK100 Natural Killer Cell Product Candidate in AML First-of-Kind Cancer
Fate Therapeutics Reports Fourth Quarter 2016 Financial Results First Subject Treated with ProTmune for GvHD Prevention IND Cleared by FDA for FATE-NK100 Natural Killer Cell Product Candidate in AML First-of-Kind Cancer Immunotherapy Derived from Engineered Pluripotent Cell Li
Read more →FATEFate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy
SAN DIEGO, March 13, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Adminis
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a confer
Read more →FATEFate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting
SAN DIEGO, March 02, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that three abstracts describing the
Read more →FATEFate Therapeutics to Present at Two Upcoming Conferences in March
SAN DIEGO, March 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it will present at two confere
Read more →FATEFate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy
Off-the-Shelf Natural Killer Cell Therapy Being Developed to Complement Standard-of-Care Monoclonal Antibody Treatment for Cancer First-of-Kind Product Candidate to be Manufactured from an Engineered Induced Pluripotent Stem Cell Line Intellectual Property Covering Compositions
Read more →FATEFate Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
SAN DIEGO, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive O
Read more →FATEFate Therapeutics Announces First Patient Treated in ProTmune™ PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease
SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first patient has been treated in its PROT
Read more →FATEFate Therapeutics Announces Private Financing
SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has entered into a definitive securities pu
Read more →FATEFate Therapeutics Announces Private Financing San Diego, CA
Fate Therapeutics Announces Private Financing San Diego, CA - November 22, 2016 - Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has
Read more →FATEFate Therapeutics Reports Third Quarter 2016 Financial Results IND Filed for FATE-NK100 Adaptive Natural Killer Cell Immunotherapy in Acute Myeloid Leukemia Orphan Drug Designations for ProTmune Granted by FDA and EMA Pr
Fate Therapeutics Reports Third Quarter 2016 Financial Results IND Filed for FATE-NK100 Adaptive Natural Killer Cell Immunotherapy in Acute Myeloid Leukemia Orphan Drug Designations for ProTmune Granted by FDA and EMA ProTmune PROTECT Clinical Protocol Amended to Facilitate Pa
Read more →FATEFate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that six abstracts highlighting the Company’s progr
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2016 Financial Results on November 7, 2016
SAN DIEGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and li
Read more →FATEFate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
Protects Cellular Composition of Lead Immunotherapy Product Candidate ProTmune™ Covers Compositions Generated Using Ex Vivo Modulation to Enhance Stem Cell Properties SAN DIEGO, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company
Read more →FATEFate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation
SAN DIEGO, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) h
Read more →FATEFate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies Unite Cellular Immunotherapy Expertise to Accelerate Clinical Translation of Off-the
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies Unite Cellular Immunotherapy Expertise to Accelerate Clinical Translation of Off-the-Shelf Products Offering Broad Patient Access Collaborat
Read more →FATEFate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive O
Read more →FATEFate Therapeutics Reports Second Quarter 2016 Financial Results Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection IND Filing for Allogeneic Memory-Like NK Ce
Fate Therapeutics Reports Second Quarter 2016 Financial Results Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection IND Filing for Allogeneic Memory-Like NK Cell Cancer Immunotherapy Planned for 2016 Announced $10.3
Read more →FATEFate Therapeutics Announces $10.3 Million Common Stock Private Placement San Diego, CA
Fate Therapeutics Announces $10.3 Million Common Stock Private Placement San Diego, CA - August 8, 2016 - Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, anno
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2016 Financial Results on August 8, 2016
SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and li
Read more →FATEFate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells
Key Patent Covers Renewable Pluripotent Cell Source for Development of Off-the-Shelf NK- and T-Cell Immunotherapies SAN DIEGO, July 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular
Read more →FATEFate Therapeutics Announces FDA Fast Track Designation for ProTmune™
SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) ha
Read more →FATEFate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research
SAN DIEGO, June 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled “Fightin
Read more →FATEFate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases
One-time Administration of Programmed Cells Demonstrates Durable Disease Correction in Type 1 Diabetes Mouse Model ToleraCyte™ Product Candidate Exhibits Enhanced Trafficking to the Pancreas and Potent Regulation of Autoreactive T Cells in Preclinical Testing Preclinical Data
Read more →FATEFate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer
SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company
Read more →FATEFate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy
Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota Program to be Presented Today at Innate Killer Summit 2016 SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutica
Read more →FATEFate Therapeutics Reports First Quarter 2016 Financial Results Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016 Adaptive NK Cell Cancer Immunotherapy to
Fate Therapeutics Reports First Quarter 2016 Financial Results Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016 Adaptive NK Cell Cancer Immunotherapy to be Featured at Innate Killer Summit in mid-May Immuno-Reg
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016
SAN DIEGO, May 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and liv
Read more →FATEFate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
SAN DIEGO, April 05, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive
Read more →FATEFate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results ProTmune Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical
Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results ProTmune Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016 Da
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016
SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and li
Read more →FATEFate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings
Poster Presentation to Highlight Anti-Tumor Properties of Ex Vivo Programmed Donor T Cells Phase 1/2 Clinical Trial of ProTmune in Mobilized Peripheral Blood HCT to Commence Enrollment in Mid-2016 SAN DIEGO, Feb. 21, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE
Read more →FATEFate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference
SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executiv
Read more →FATEFate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today the U.S. Food and Drug Administration (FDA) has
Read more →FATEFate Therapeutics to Present at Biotech Showcase 2016
SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President a
Read more →FATEFate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation
Supportive Interim Data from ProHema PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening Complications in Mobilized Peripheral Blood HCT ProTmune to Advance into Phase 1/2 Clinical T
Read more →FATEFate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference
SAN DIEGO, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President an
Read more →FATEFate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting
First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016 Poster Presentations to Highlight Preclinical Findings and Potential Therapeutic and Pharmacoeconomic Value Propositions in HCT SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIR
Read more →FATEFate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015
SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that it will present its strateg
Read more →FATEFate Therapeutics Reports Third Quarter 2015 Financial Results Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting First-in-Human Clinical Trial of PRO
Fate Therapeutics Reports Third Quarter 2015 Financial Results Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting First-in-Human Clinical Trial of PROTMUNE to Prevent Acute GvHD and Severe Infections Planned
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2015 Financial Results on November 3, 2015
SAN DIEGO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, today announced that the Company will host a co
Read more →FATEFate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions
SAN DIEGO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that the U.S. Patent and Tradem
Read more →FATEFate Therapeutics Announces Leadership Transition Scott Wolchko, a Fate Founder, to Succeed Christian Weyer as President and CEO Effective
Fate Therapeutics Announces Leadership Transition Scott Wolchko, a Fate Founder, to Succeed Christian Weyer as President and CEO Effective December 1, 2015 Additional Leadership Changes Enhance Fate Executive Team SAN DIEGO, CA October 12, 2015 Fate Therapeutics, Inc. (NASDAQ
Read more →FATEFate Therapeutics to Present at September Investor Conferences
SAN DIEGO, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D.,
Read more →FATEFate Therapeutics Reports Second Quarter 2015 Financial Results Interim Data from PROHEMA PUMA Study Show Reduction in Severe Infections across Multiple Pathogen Types First Pediatric Subject Treated in PROHEMA PROVIDE S
Fate Therapeutics Reports Second Quarter 2015 Financial Results Interim Data from PROHEMA PUMA Study Show Reduction in Severe Infections across Multiple Pathogen Types First Pediatric Subject Treated in PROHEMA PROVIDE Study of CNS Cellular Replacement Strategic Research Colla
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5, 2015
SAN DIEGO, July 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conf
Read more →FATEFate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research
SAN DIEGO, July 15, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced today that it has named Dr. Stewart Abb
Read more →FATEFate Therapeutics and Regents of the University of Minnesota Enter Into Research Collaboration for Translation of Natural Killer Cell Cancer Immunotherapies
"Adaptive" Natural Killer Cell Therapeutics to be Advanced as Antibody-Mediated Cancer Therapy Genetically-Engineered Induced Pluripotent Stem Cell-derived Natural Killer Cells to be Developed as Off-the-Shelf Targeted Immunotherapy Fate Therapeutics Holds an Exclusive Option t
Read more →FATEFate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases
SAN DIEGO, June 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE) announced today that it has entered into a two-year sponsored research agreement with Boston Children's Hospital to accelerate the development of an adoptive immunoregulatory cell therapy to treat a
Read more →FATEFate Therapeutics Reports First Quarter 2015 Financial Results Strategic Research Collaboration Established with Juno Therapeutics to Apply Small Molecule Modulators for Programming CAR and TCR Immunotherapies Additional
Fate Therapeutics Reports First Quarter 2015 Financial Results Strategic Research Collaboration Established with Juno Therapeutics to Apply Small Molecule Modulators for Programming CAR and TCR Immunotherapies Additional Data from Ongoing Phase 2 PUMA Study of PROHEMA Continue
Read more →FATEJuno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies Alliance Utilizes Fate s Hematopoietic Cell Programming Platform t
Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies Alliance Utilizes Fate s Hematopoietic Cell Programming Platform to Identify Small Molecule Modulators for Juno s Leading Gen
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015
SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a confer
Read more →FATEFate Therapeutics to Present at Deutsche Bank 40th Annual Health Care Conference
SAN DIEGO, April 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.
Read more →FATEFate Therapeutics to Present at 14th Annual Needham Healthcare Conference
SAN DIEGO, April 8, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S
Read more →FATEFate Therapeutics to Present at the Regen Med Investor Day
SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.
Read more →FATEFate Therapeutics Reports Year-End 2014 Financial Results Favorable Phase 2 Interim Data From Ongoing PUMA Study of PROHEMA in Adult Hematologic Malignancies Reported in December 2014 PROHEMA Clinical Data in Pediatric H
Fate Therapeutics Reports Year-End 2014 Financial Results Favorable Phase 2 Interim Data From Ongoing PUMA Study of PROHEMA in Adult Hematologic Malignancies Reported in December 2014 PROHEMA Clinical Data in Pediatric Hematologic Malignancies and Rare Genetic Disorders Expecte
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2014 Financial Results on March 12, 2015
SAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conf
Read more →FATEFate Therapeutics Expands and Strengthens Leadership Team
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Wendy Levin, M.D., M.S. will
Read more →FATEFate Therapeutics to Present at Cowen & Company 35th Annual Health Care Conference
SAN DIEGO, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S
Read more →FATEFate Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S.
Read more →FATEFate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline
Primary Endpoint Read-outs from Adult PUMA and Pediatric PROMPT Studies of PROHEMA in Hematologic Malignancies Expected in mid-2015 Topline Data from Pediatric PROVIDE Study of PROHEMA in Rare Inherited Metabolic Disorders Expected in 2015 IND Filing for New Programmed Mobilize
Read more →FATEFate Therapeutics to Present at Biotech Showcase 2015
SAN DIEGO, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S.
Read more →FATEFate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study of PROHEMA in Adults with Hematologic Malignancies Key Metrics of Neutrophil Engraftment Improved in PROHEMA Arm Independent Data Monitoring Commit
Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study of PROHEMA in Adults with Hematologic Malignancies Key Metrics of Neutrophil Engraftment Improved in PROHEMA Arm Independent Data Monitoring Committee Supports Continuation of Study Enrollment Full Result
Read more →FATEFate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood
SAN DIEGO, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, will present today an overview of the effects of using its nutrient-rich
Read more →FATEFate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood
SAN DIEGO, Dec. 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, released preclinical data today highlighting the pharmacological propert
Read more →FATEFate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference
SAN DIEGO, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief
Read more →FATEFATE THERAPEUTICS, INC. Moderator: Scott Wolchko
FATE THERAPEUTICS, INC. Moderator: Scott Wolchko Operator: Welcome to Fate Therapeutics third quarter 2014 financial results conference call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Fate s
Read more →FATEFate Therapeutics Reports Third Quarter 2014 Financial Results Phase 1b PROMPT Study in Pediatric Hematologic Malignancies Open for Enrollment Second Data Review in Phase 2 PUMA Study Expected in 4Q14 Presenting Effects
Fate Therapeutics Reports Third Quarter 2014 Financial Results Phase 1b PROMPT Study in Pediatric Hematologic Malignancies Open for Enrollment Second Data Review in Phase 2 PUMA Study Expected in 4Q14 Presenting Effects of Ex Vivo Programming on Mobilized Peripheral Blood at A
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2014 Financial Results on November 11, 2014
SAN DIEGO, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live au
Read more →FATEFate Therapeutics to Present at Nomura Biotechnology Conference
SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief
Read more →FATEFate Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference
SAN DIEGO, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief
Read more →FATEFate Therapeutics Reports Second Quarter 2014 Financial Results First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment PROMPT and PROVIDE Studies of PROHEMA in Pediatric Patients to Initia
Fate Therapeutics Reports Second Quarter 2014 Financial Results First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment PROMPT and PROVIDE Studies of PROHEMA in Pediatric Patients to Initiate in 2H14 San Diego, CA August 12, 2014 Fate Therapeutic
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2014 Financial Results on August 12, 2014
SAN DIEGO, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live au
Read more →FATEFate Therapeutics Secures Up to $20 Million in Debt Financing
SAN DIEGO, July 31, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has completed a long-term debt financing of up
Read more →FATEFate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders
SAN DIEGO, July 29, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has cl
Read more →FATEFate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders
SAN DIEGO, June 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has submitted an investigational new drug (IND)
Read more →FATEFate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium
SAN DIEGO, June 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that potential clinical applications of its ex vivo appr
Read more →FATEFate Therapeutics to Present at Jefferies 2014 Global Healthcare Conference
SAN DIEGO, May 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief
Read more →FATEFate Therapeutics Reports First Quarter 2014 Financial Results Phase 2 PUMA Study of PROHEMA in Adult Hematologic Malignancies Enrolling Patients Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cle
Fate Therapeutics Reports First Quarter 2014 Financial Results Phase 2 PUMA Study of PROHEMA in Adult Hematologic Malignancies Enrolling Patients Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cleared by FDA IND Submission for Study of PROHEMA in Rare G
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014
SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live aud
Read more →FATEFate Therapeutics to Present at Deutsche Bank 39th Annual Health Care Conference
SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chie
Read more →FATEFate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients
SAN DIEGO, April 23, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has c
Read more →FATEFate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics
SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Patent and Trademark Office (PTO) has is
Read more →FATEFate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Phase 2 PUMA Study of PROHEMA Initiated - Interim Data Expected in 2H14 Clinical Trial of PROHEMA in Lysosomal Storage Disorders to Begin in 2
Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Phase 2 PUMA Study of PROHEMA Initiated - Interim Data Expected in 2H14 Clinical Trial of PROHEMA in Lysosomal Storage Disorders to Begin in 2H14 Encouraging Clinical Data Published Highlighting the
Read more →FATEFate Therapeutics Appoints Dr. Robert S. Epstein to its Board of Directors
Fate Therapeutics Appoints Dr. Robert S. Epstein to its Board of Directors SAN DIEGO, March 17, 2014 Fate Therapeutics, Inc. (Nasdaq: FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced tod
Read more →FATEFate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies
First Patient Enrolled in PUMA Study Approved for Conduct at Ten Leading U.S. Centers Interim Data Expected in 2H14 SAN DIEGO, March 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adul
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014
SAN DIEGO, March 11, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live
Read more →FATEFate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
SAN DIEGO, March 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the publication of an article in the journal Stem Cell
Read more →FATEFate Therapeutics Observes Rare Disease Day 2014
SAN DIEGO, Feb. 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, is joining the Muscular Dystrophy Association (MDA) and other advocacy
Read more →FATEFate Therapeutics to Present at Upcoming March Conferences
SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief
Read more →FATEFate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R)
SAN DIEGO, Feb. 26, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the release of new data on the observed effects of ex v
Read more →FATEFate Therapeutics Reports Third Quarter 2013 Financial Results Cleared Key Milestones for Resumption of ProHema Phase 2 Clinical Trial Selected Wnt7a Protein Analogs for Advancement into IND-Enabling Activities Extended
Fate Therapeutics Reports Third Quarter 2013 Financial Results Cleared Key Milestones for Resumption of ProHema Phase 2 Clinical Trial Selected Wnt7a Protein Analogs for Advancement into IND-Enabling Activities Extended Breadth of Patent Protection for HSC Modulation Platform
Read more →FATEFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2013 Financial Results on November 13, 2013
SAN DIEGO, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live au
Read more →FATEFate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
SAN DIEGO, Oct. 4, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced the closing of its previously announced initial public o
Read more →FATEFate Therapeutics to Present at World Muscle Society Congress
SAN DIEGO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that its Senior Vice President, Early Program Developmen
Read more →FATEFate Therapeutics, Inc. Announces Pricing of Initial Public Offering
SAN DIEGO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced the pricing of its initial public offering of 6,666,667
Read more →FATEFate Therapeutics Files Registration Statement for Proposed Initial Public Offering
SAN DIEGO, Aug. 14, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange C
Read more →FATEFate Therapeutics Presents Preclinical Efficacy Data for WNT7A-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference
SAN DIEGO, April 22, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the presentation of preclinical data from its WNT7a protein analog program for the treatment
Read more →FATEFate Therapeutics to Present at Cowen & Co. 33rd Annual Health Care Conference
SAN DIEGO, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an ove
Read more →FATEFate Therapeutics to Present at 15th Annual BIO CEO & Investor Conference
SAN DIEGO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will be presenting a
Read more →Competitive Position
How FATE ranks across every disease it competes inCompetitive Position is a premium feature
See how FATE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial